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Abstract 
Progressive X-linked muscular dystrophy represents the most commonly inherited 
neuromuscular disorder in humans. Although the primary abnormality lies with the loss 
of dystrophin and reduction of its associated glycoprotein complex, secondary 
alterations in metabolic pathways, cellular signalling and ion homeostasis regulation 
cause fibre degeneration leading to severe muscle weakness. Skeletal muscle 
deteriorates to the extent that sufferers are wheelchair bound by early adulthood and 
severe diaphragm degeneration can lead to respiratory failure. Therapy in this area has 
lengthened life-span but at a more advanced stage of the disease, most Duchenne 
muscular dystrophy patients suffer cardiomyopathic complications. 
The purpose of this study was to carry out proteomic profiling on differentially affected 
dystrophic tissues. Differences in protein concentration levels of the severely affected 
cardiac muscle and the naturally protected extraocular muscle were used to explore 
pathogenesis of the disease. 
A mass spectrometry-based approach combined with the highly sensitive difference 
in-gel electrophoresis technique was used to reveal changes and identify novel 
biomarkers in the dystrophic tissues. Following the pathogenesis of the disease the 
naturally protected tissue displayed only moderate changes in protein concentration 
expression. With a replacement of dystrophin with its homologue utrophin, restoration 
of β-dystroglycan was observed along with an increased concentration in heat shock 
proteins. While the severely affected cardiac muscle exhibited drastic decreases in the 
expression levels of many proteins involved in energy metabolism including adenylate 
kinase and many ATP synthase isoforms. Reduced concentrations were also observed 
in numerous contractile proteins and intermediate filament proteins. With the loss of 
these structural elements, a drastic increase in stress proteins was observed within 
dystrophic myofibrils compared to normal fibres.  
This thesis has successfully identified novel biomarkers that may be used to 
determine suitability of new treatments or therapies of muscular dystrophy. 
 1 
 
1 Introduction 
Muscle is the most abundant tissue in the body. It is the effector organ of the nervous 
system resulting in the transformation of potential energy into contractile force. The 
four main muscle types divide into two groups: those that we control voluntarily, 
skeletal muscle for mobility and posture, and those under control of the central nervous 
system namely the smooth muscle, heart and myoepithelial cells of glands. In this 
study, we looked at a subtype of skeletal muscle, the striated extraocular muscle and 
also at the cardiac muscle of a murine animal model. 
 
1.1 Contractile muscle structure 
A muscle is made up of many muscle fibres. A single muscle fibre is composed of 
bundles of myofibrils. The striated muscle pattern of skeletal muscle comes from the 
alignment of thick and thin filaments. This regular lattice pattern makes up the 
sarcomeres within the myofibril (Huxley and Niedergerke, 1954). The sarcomere 
structure consists of the thick filament located in the centre and surrounded by six thin 
filaments (see Figure 1-1). The overlap of these thick and thin filaments is visualized as 
a darkly stained area known as the A-band lying in the centre of each sarcomere. The 
centre has a narrow M-line where proteins link together the thick filaments of myosin 
chains. Also contained in the A-band is the presence of the H-zone where there is an 
absence of thin actin filaments. The end of each sarcomere is marked by the Z-line 
where a section of proteins anchor the thin filaments. Either side of the Z-line is the 
lightly stained due to the absence of any thick filaments and contains only thin filaments 
and is known as the I-band (Sjostrom and Squire, 1977) . It was proved in the 1950s 
that the lengths of these thick and thin filaments did not change during contraction of 
the muscle; therefore it was thought that contractile force was developed between the 
overlapping sections. With the development of electron microscopy the source of force 
was elucidated. The projecting myosin heads in the A-band provide the force with which 
 2 
muscle contracts. The projections form cross-bridges with the actin of the thin filament 
and shorten the sarcomere by causing the thin filaments to slide over the thick filaments 
(Huxley, 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-1 Contractile muscle structure 
Contractile elements make up the repeating sarcomeres, which align to form the 
myofibrils. The thick filaments of the A band are composed of intertwined myosin 
chains surrounded by the thin actin filaments. (image taken from ucl.ac.uk) 
1.2 Sliding filament mechanism 
Contraction of the muscle involves two types of filaments. Thick filaments consist of 
myosin and myosin heads and thin filaments consist of actin, tropomyosin and troponin 
(Tp). Calcium released from the potential activated sarcoplasmic reticulum (SR), binds 
Troponin C (TpC), causing tropomyosin to expose an actin binding site. This eliminates 
the inhibition of actin to bind to myosin. A TpT/TpI interaction with tropomyosin alters 
the conformation of contractile actin and allows a myosin head to interact with actin 
 A Band  A Band 
 3 
initiating a cross bridge (Rayment et al., 1993).  Two globular heads linked by a coil 
make up the myosin head. ATP binds the cleft between the heads. It is hypothesised 
that the energy is gained by (i) myosin binding actin, (ii) that the cleft opens releasing 
the hydrolysed phosphate from ATP and that (iii) the cleft closes providing a 
conformational change, creating a ‘powerstroke’ that pulls on the thin filament (Veigel 
et al., 1999). ADP is then released and ATP binds again, causing the head to release 
actin, bringing the myosin head back to its original position and becoming energized 
again. In the presence of calcium, this cycle causes continued shortening of the muscle 
fibres by interaction of many myosin head/actin cross bridges. Either side of the M-line 
the cross bridges lie in opposite directions, each side is oriented with the arm end 
toward the M-line and the head pointing away. The thick and thin filaments do not 
change length but the H zone and I band shorten and the degree of shortening 
corresponds with the level of contraction (Reedy, 2000) (see Figure 1-2).  
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Figure 1-2 Sliding filament theory 
A conformational change occurs to tropomyosin following the binding of calcium to 
troponin C. A actin binding site is exposed and the myosin head forms a crossbridge. 
The thin filament slides over the thick filament causing muscle shortening. (image from 
edoc.hu-berlin.de) 
 
1.3 Skeletal muscle excitation-contraction coupling 
Before a muscle can contract a series of action potentials along a nerve must occur to 
cause the release of calcium from the stores within the myofibril. An action potential 
above a sufficient threshold travels along the axon of a motor neuron. Waves of 
activation of voltage-gated channels transmit the potential until it reaches the axon 
terminal where it activates calcium voltage gated channels. The calcium released in the 
end-plate causes acetycholine transmitter molecules to be released from the terminal 
into the synaptic cleft, which in turn bind acetycholine receptors along the post synaptic 
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junction (Farley and Miles, 1977). The potential is then carried along the muscle surface 
membrane where voltage dependent channels are activated, causing sodium ions to 
flux out of the muscle and potassium ions move into the sarcoplasm. The sodium ions 
amplify the potential along the sarcolemma and it is carried down into invaginations 
known as transverse tubules (T-tubules). These invaginations lie between the termini of 
sarcoplasmic reticulum (SR) (Cooke, 1986). Depolarization of the T-tubules is sensed 
by the α1s-dihydropyridine receptor (DHPR). A conformational change then allows the II-
III loop domain of the DHPR to physically interact with the ryanodine receptor (RyR) on 
the SR (Tanabe et al., 1990). Transient opening of skeletal muscle, RyR1 allows 
calcium storage bodies from the lumen of the SR to release calcium along a steep 
gradient into the cytosol (Meissner and Lu, 1995). The increase in cytosolic calcium 
causes conformational changes to tropomyosin that allows the interaction of the myosin 
head with actin (Cooke, 1986).  
 
 
Figure 1-3 Voltage-gated action potential 
An impulse activates voltage-gated channels along the sarcolemma and into 
transverse tubules (t-tubules).  Calcium activates the L-type channel, which physically 
interacts with the ryanodine receptor (RyR) of the sarcoplasmic reticulum (SR). Storage 
bodies within the SR release calcium, which in turn can interact with the contractile 
elements of the myofibril. www.sim-bio.org 
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1.4 The cardiac action potential 
Cardiac cells are branched and adjacent cell membranes are intertwined at areas 
known as intercalated discs (ID). The ID contains gap junctions, which allow the 
transfer of ions from one cell to another. This allows an action potential to travel from 
one muscle cell to another causing an electrochemical syncytium, whereby all the heart 
cells can act as one. Cardiac cells do not carry potential down nerves and across 
neuromuscular junctions. Instead, a regular impulse is generated spontaneously in the 
sinoatrial node and transmitted through specialized pacemaker cells known as Purkinje 
fibres. As the atria contract the action potential is carried through the intercalated discs 
throughout the myocardium, a second threshold is overcome in the atrioventricular 
node and this causes the contraction of the ventricles (Shih, 1994). 
 
 
1.5 Cardiac excitation-contraction mechanism 
In cardiac muscle, the contraction of myofibrils is activated by the influx of calcium 
ions into the muscle, but there are a number of differences to the mechanisms used by 
skeletal muscle. In cardiac muscle the DHPR complex does not couple directly with the 
SR release channel, instead the cardiac specific α1C-DHPR allows a small amount of 
calcium to enter the cytosol via a calcium gradient. This calcium influx causes the 
cardiac isoform of the ryanodine receptor, RyR2, to open and release large amounts of 
calcium from the SR (Wasserstrom, 1998). The calcium released then activates 
neighbouring RyR and thus amplifies the signal. This is known as ‘the calcium induced 
calcium release mechanism’ and is thought to be the dominant pathway in cardiac 
muscle. When the calcium concentration increases sufficiently, calcium then binds TpC 
within the sarcomere, which induces sliding of the filaments and shortening of the 
sarcomere (Bers, 2000).  
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The re-uptake of calcium must occur for the muscle to relax. The calcium 
concentration must decrease so that dissociation occurs from troponin. Calcium is 
removed from the cytosol by calcium buffering systems. Re-uptake of free cytosolic 
calcium occurs by various binding moieties including, the cardiac sarcoplasmic 
reticulum Ca2+ ATPase 2 (SERCA2) pumping calcium back into the lumen of the SR 
and the cardiac isoform sodium/calcium exchanger (NCX) returning free calcium to 
mitochondria and extruding it across the sarcolemma membrane (Bassani et al., 1994). 
Bers (2000) showed that in rabbit ventricular myocytes, SERCA2 removes 70% of the 
calcium and the NCX 28% from the cytosol, they demonstrated that two calcium ions 
were removed per ATP molecule using SERCA2 and the NCX indirectly removes one 
calcium ion per ATP. This is therefore an energy expensive mechanism and it is thought 
a vast number of these pumps line the SR and that the number of pumps equals the 
number of calcium ions released from a single twitch.  
 
 
1.6 Dystrophin  
Contractile muscle force is reduced in damaged cells. The cytoskeleton of a cell is 
composed of actin filaments that provide a structural network below the membrane. 
Repeated muscle contraction damages membranes not supported by a cytoskeletal 
network (Lovering and De Deyne, 2004). Dystrophin binds actin filaments in the 
structural network to the extracellular matrix thus anchoring the glycoprotein complex in 
the membrane of a myofibre. The loss of the dystrophin protein causes reorganisation 
of the membrane. The membrane attempts to replace the missing proteins by 
substitution with ion pores. Calcium ions from muscle contraction cause further damage 
to a dystrophic cell.  
 Genetic alterations in the dystrophin gene lead to the dystrophic phenotype in 
muscle. The dystrophin 14kb mRNA codes for a 427kDa protein (Hoffman et al., 1987). 
Dystrophin contains four domains; the amino terminal whose sequence has been 
conserved from cytoskeletal actin binding proteins and binds cortical actin in myofibrils. 
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The “rod domain” which contains 24 helical repeats and four hinge domains, which give 
it a flexible characteristic (Koenig et al., 1988; Koenig and Kunkel, 1990). Both these 
domains make up 14% coverage of the whole dystrophin protein. The third domain is a 
cysteine-rich domain which binds β-dystroglycan and α-dystrobrevin (Rentschler et al., 
1999). Finally, a carboxyl terminal domain is a unique sequence to the dystrophin 
protein. Utrophin, is an autosomal protein with similar homology to the dystrophin 
protein. Both actin binding proteins, bind dystrophin-associated proteins dystrobrevin 
and syntrophin (Tinsley et al., 1992) (see Figure 1-4). Three full-length dystrophin 
proteins are transcribed by three alternative promoters and are Dp427 (B), Dp427 (M) 
and Dp427 (P) and found in the brain, muscle and Purkinje cells respectively. They 
differ in their amino terminal end sequences (Boyce et al., 1991; Gorecki et al., 1992; 
Yaffe et al., 1992). Four internal promoters produce truncated isoforms of dystrophin. 
These transcribe Dp260, a 260kDa protein found in the retina, Dp140 located in the 
brain, Dp116 transcribed in Schwann cells and Dp71 transcribed ubiquitously 
throughout non-muscle cells. These isoforms each have a unique amino terminal end 
and all contain the conserved region of the carboxyl domain of full-length dystrophin 
(Byers et al., 1993; D'Souza et al., 1995; Lidov et al., 1995). 
Dystrophin localizes to the sarcolemma on the cytoplasmic side of the membrane 
(Zubrzycka-Gaarn et al., 1988). It interacts within the sub-sarcolemmal cytoskeleton, 
the costameres, of myofibrils via its actin binding domain and the cysteine-rich domain 
links the extracellular dystroglycan complex via ß-dystroglycan (Campbell, 1995). 
Dystrophic muscle becomes weak, with sarcolemmal disruptions and costameric 
reorganization. 
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Figure 1-4 Dystrophin and Utrophin domain structures 
Shown is a diagram comparing the domain regions and similarity of murine dystrophin 
and utrophin. Utrophin lacks modules of the rod domain corresponding to helical 
repeats 15 to 19 in dystrophin. The structures contain an amino terminal (AT) domain, 
four hinge regions (H1-H4) within the rod domain of up to 24 helical repeats, a 
cysteine-rich (CT) domain and finally a carboxyl terminal (CT) domain. 
 
1.7 Dystrophinopathies 
Genetic alterations in dystrophin and various dystrophin-associated proteins are 
responsible for a number of neuromuscular disorders (see Figure 1-5). The effect is 
seen through many different muscle types although the end-stage phenotype is usually 
caused by secondary effects due to mechanical stresses exacerbated by altered ion 
handling brought about by abnormal excitation-contraction coupling, sarcolemmal 
fragility, muscle weakness and necrosis (Carlson and Makiejus, 1990; Weller et al., 
1990; Williams and Bloch, 1999). The primary disorder is due to the absence of 
dystrophin and subsequently the loss of various dystroglycan proteins anchored by the 
dystrophin protein.  
Dystrophin is the largest gene in the human genome, consisting of 14 kilobases 
encoding a 3,685 amino acid protein (Koenig et al., 1988). Due to its large size 30-40% 
of the genetic alterations are spontaneous, most of these being deletions with about a 
third being point mutations (Den Dunnen et al., 1989). Being on chromosome Xp21 it is 
an X-linked disease, with about 1:3500 males being affected worldwide. The onset of 
difficulties in walking begins around 1-5 years of age, with weakness in limbs leading to 
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loss of ambulation by teenage years. Enlargement of the limbs occurs due to the 
infiltration of adipose and connective tissue. Serious cardiac implications emerge by 
late teenage years and respiratory and or cardiac failure represents a significant 
number of deaths from Duchenne muscular dystrophy (DMD) occurring during the 
second decade (Emery, 2002).  
A partial absence of dystrophin leads to the milder Becker muscular dystrophy (BMD). 
The onset of the disease is later, with moderate weakness in adults. Walking is affected 
by the mid teens with cardiac problems beginning by 20 years of age. Patients can 
survive through to 40 and 50 years old (Monaco et al., 1988).  
X-linked dilated cardiomyopathy muscular dystrophy is an abnormality on the same 
gene as DMD. However, it involves the promoter on the 5’ end of the gene that 
produces the cardiac specific dystrophin protein. Little or no skeletal muscle disease is 
observed during this disease with males suffering cardiac failure in their 20’s (Towbin et 
al., 1993).  
Other muscular dystrophies have been recorded due to loss of dystrophin-associated 
proteins. Sarcoglycanopathies are due to the loss of proteins from the tetrameric 
sarcoglycan complex leading to a range of limb-girdle muscular dystrophies (LGMD). 
These are progressive skeletal muscle diseases affecting shoulder and pelvic girdle 
muscles. Different types of LGMD are linked to absence in each of the different 
sarcoglycan isoforms with some of the disorders associated with cardiac involvement 
(Lim et al., 1995; Jung et al., 1996). Sarcospan deficiency has shown no human 
myopathy. 
Laminin, the protein that interacts with the dystrophin-glycoprotein complex (DGC) via 
α-dystroglycan, proves to be the protein in deficiency in congenital muscular dystrophy. 
Children display weakness at birth and although is it not a progressive disease, children 
usually cannot walk (Minetti et al., 1996).  
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Figure 1-5 Synopsis of neuromuscular disorders with primary abnormalities in the dystrophin-
glycoprotein complex. 
Shown are a diagrammatic presentation of the dystrophin-associated protein complex 
and a list of muscle proteins with a genetic defect in muscular disorders. Genetic 
alterations in laminin (LAM), γ-sarcoglycan (γ-SG), α-SG, β-SG or δ-SG are associated 
with congenital muscular dystrophy (CMD) and subtypes 2C, 2D, 2E and 2F of limb-
girdle muscular dystrophy (LGMD), respectively. Primary defects in the Dp427 isoform 
of dystrophin in the actin membrane cytoskeleton (AMC) cause severe Duchenne 
muscular dystrophy (DMD), benign Becker muscular dystrophy (BMD) and X-linked 
dilated cardiomyopathy (XLDCM). The Dp427 isoform of dystrophin also binds 
syntrophin (SYN) and dystrobrevin (DYB) proteins, mutations in which have no known 
neuromuscular disorders. 
 
 
1.8 Dystroglycan complex 
The dystrophin-associated glycoprotein complex (DAGC) is made up of three 
complexes. The dystroglycan complex which serves to link the extracellular matrix to 
the cytoplasm, the sarcoglycan complex which stabilizes the DAGC within the 
sarcolemma and the dystrophin-containing complex which links the complex to actin in 
myofibrils. The DAGC complex was identified after dystrophin was separated using 
wheat germ agglutinin chromatography (Campbell and Kahl, 1989). It was shown that 
dystrophin was tightly associated to a glycoprotein complex in the sarcolemma. An 
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overview of the structure of this DAGC is diagrammatically represented in Figure 1-6. 
The largest of these proteins, the 156kDa protein α-dystroglycan (αDG) was found in 
the extracellular matrix and it bound to laminin via a calcium dependency (Ibraghimov-
Beskrovnaya et al., 1992; Hohenester et al., 1999). It also had a physical interaction 
with the 43kDa protein β-dystroglycan (βDG) (Rentschler et al., 1999). The carboxyl 
terminus of the transmembrane protein, βDG is located on the cytoplasmic side of the 
sarcolemma and the 15 C-terminal amino acids of this domain bind directly to 
dystrophins’ cysteine-rich domain (Jung et al., 1995). Calveolin-3, another 
transmembrane protein, competes with dystrophin for the βDG binding site in non-
contractile muscle (Sotgia et al., 2000). 
Five proteins were identified in the syntrophin family, the α-syntrophin, β1- and β2 –
syntrophins and the γ1- and γ2- syntrophins (Adams et al., 1993; Ahn et al., 1994; Ahn et 
al., 1996; Piluso et al., 2000). They are found distributed differently in muscle, and 
dystrophin and dystrobrevin contain syntrophin-binding sites (Newey et al., 2000).  
Two genes encode the dystrobrevin family, transcribing α- and β-dystrobrevin. These 
cytoplasmic proteins bind syntrophin and dystrophin via the carboxyl end (Albrecht and 
Froehner, 2002). The dystrobrevins have a number of similarities to dystrophin. 
Namely, a carboxyl terminus of similar homology to the dystrophin protein and also has 
a number of promoters like dystrophin that produce full-length isoforms proteins 
(Wagner et al., 1993). Alpha-dystrobrevin binds dystrophin in the cytoplasm whereas β-
dystrobrevin is found in non-muscle tissues (Blake et al., 1999; Loh et al., 2000). 
The sarcoglycan complex comprises four transmembrane glycoproteins and the 
sarcospan protein (Crosbie et al., 1997; Lim and Campbell, 1998). The α-sarcoglycan 
protein is found in skeletal and cardiac muscle, whereas other sarcoglycans can be 
found in smooth muscle (Barresi et al., 2000). The sarcospan protein is tightly linked to 
this complex of proteins, which is anchored by the DGC in the sarcolemma. The DGC 
complex appears to be maintained with the loss of sarcospan, as shown with 
sarcospan knockout mice, therefore appears not essential in maintaining the integrity of 
the membrane (Duclos et al., 1998; Lebakken et al., 2000).  
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Figure 1-6 Overview of the structure of the dystrophin-glycoprotein complex form skeletal 
muscle and its involvement in the molecular pathogenesis of X-linked muscular dystrophy. 
Shown is a diagram of the supramolecular dystrophin complex of the sarcolemma (SL) 
that links the actin membrane cytoskeleton (AMC) of the cytosol (CYT) to the 
extracellular matrix (ECM) component laminin (LAM). The full-length dystrophin isoform 
Dp427 binds directly to syntrophins (SYN), dystrobrevins (DYB) and the integral 
glycoprotein β-dystroglycan (β−DG), which in turn interacts with the extracellular 
laminin-binding protein α-dystroglycan (α-DG). Other Dp427-associated proteins are 
represented by sarcospan (SS) and the sarcoglycans (α/β/γ/δ-SG). Shown also located 
within the muscle cell is an invagination of the sarcolemma, the transverse tubule (TT) 
leading to the sarcomere (SM) containing the contractile elements, which is surrounded 
by the sarcoplasmic reticulum. Deficiency of Dp427 in muscle fibres from Duchenne 
muscular dystrophy (DMD) patients and its animal model, the dystrophic mdx mouse, 
cause a drastic reduction in the dystrophin-associated glycoprotein complex (DAGC). 
Loss of the linkage between the ECM and AMC results in a weakened SL membrane 
system, triggering various cellular abnormalities and finally severe muscular 
degeneration 
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1.9 Animal model of Duchene muscular dystrophy 
The murine X chromosome-linked (MDX) mouse model is internationally recognized 
as a suitable model for the study of DMD/BMD. Absence of the 427kDa protein 
dystrophin affects muscle and non-muscle tissue. This defect causes muscular 
dystrophies to varying effect in different muscles, with the diaphragm being most 
severely affected (Stedman et al., 1991). The DMDmdx mouse has a mutation on exon 
23 of the dystrophin gene (Xp21) causing an absence in the Dp427 protein-Dystrophin. 
A single base pair change in the exon from cysteine to thymine creates a termination 
codon. This point mutation in the dystrophin gene results in a truncated protein of only 
115kDa in length, which may attach to the extracellular dystroglycan complex conferring 
some membrane stability but with two-thirds of the rod and terminal domain missing, it 
would be unable to bind to the intracellular actin cytoskeleton. The MDX mouse does 
express four shorter isoforms containing the C-terminal end. These isoforms are 
expressed in non-muscle tissues and these various tissues show less severe 
pathologies of the dystrophy; this could possibly be explained by the production of 
these dystrophin isoforms. This may explain the milder pathology in the MDX mouse 
compared with DMD patients (Sicinski et al., 1989).  
The MDX3cv mouse, a strain lacking the four shorter isoforms does not show more 
severe abnormalities than MDX mice in skeletal muscle as the isoforms are produced in 
non-muscle tissue. Shorter isoforms of the dystrophin protein can be produced from the 
Xp21 gene, and the MDX3cv model mouse, deficient in dystrophin, has an additional 
point mutation on exon 65, which removes the isoforms Dp260, Dp140, D116 and 
Dp71. The proteins of 260, 140 and 116 are produced in the retina, brain and Schwann 
cells, respectively, and the 71kDa protein expressed in most tissues except skeletal 
(Cox et al., 1993; Rafael et al., 1999).  
Utrophin, a similar protein with significant gene homology to dystrophin has been 
shown to be up-regulated in MDX strains of mice (Blake et al., 2002). An autosomal 
protein may be expressed in all tissues and is therefore not subject to the X-linked 
mutation. Although down-regulated after birth, utrophin is thought to compensate for the 
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absence of dystrophin as it is up-regulated three fold in the MDX extraocular muscle 
and found in the sarcolemma of regenerating muscles. The extraocular muscles of the 
MDX mouse appear free from the pathology of Duchenne muscular dystrophy, even 
though they are a skeletal muscle lacking in dystrophin (Porter et al., 1998). Therefore, 
utrophin is thought to play a compensatory role in MDX and MDX3cvmouse models, 
replacing dystrophin to some extent in skeletal muscles and rescuing the dystrophic 
mouse. Utrophin knockout mice, utr/mdx and utr/mdx3cv show more severe pathology to 
DMD than their single knockout counterparts, although it appears that the shorter 
isoforms produced in MDX rescue the non-muscle tissue only but the utr/mdx3cv mice 
lack utrophin and all isoforms of dystrophin do not live past 20 weeks of age (Deconinck 
et al., 1997; Rafael et al., 1999). 
 
1.10 Proteomics 
The word ‘Proteome’ comes from two words ‘protein’ and ‘genome’. Proteomics is the 
study of the entire protein complement from one organism. This includes all the 
modifications made to any number of proteins. Translation of the nucleotide sequence 
has been shown not to match fully the proteins produced (Anderson and Seilhamer, 
1997). This is because the proteome is subject to environmental influences and can act 
to apply post-translational modifications (PTM) to adapt to changing situations. 
Therefore, proteomics can be a useful tool in describing the changing expression of 
proteins in an organism subject to disease. Regardless of the starting material used 
there are a number of techniques which must be optimized. These include sample 
preparation, separation, imaging and characterization. 
1.10.1 Sample preparation 
This first step in the study of the proteome requires the solubilisation of the sample 
proteins. The sample should be homogenized into a suitable lysis buffer. The buffer 
must be capable of reducing bonds and usually contains protease inhibitors to inhibit 
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the inherent proteases in the sample (Rabilloud, 1996). Any modifications introduced, 
via salts or temperature can influence spot pattern during two-dimensional (2D) gel 
electrophoresis and therefore need to be kept to a minimum. There is no standard lysis 
buffer suitable for all tissue solubilisation and each sample should be optimized to its 
most suitable reducing buffer. Disruption of protein-protein interactions can be caused 
by a combination of reductants and detergents. Reducing agents such as dithiothreitol 
(DTT) break disulphide bridges. Chaotropic reagents like urea and thiourea disrupt 
hydrogen and hydrophobic bonds (Rabilloud, 1998). Other additions commonly used 
are detergents and ampholytes, which disrupt membranes and other hydrophobic 
bonds and further inhibit reformation of bonds by maintaining pH levels and scavenging 
cyanate artifacts produced by carbamylation of urea.   
1.10.2 2D gel electrophoresis 
Two-dimensional electrophoresis allows separation and subsequent identification of 
proteins in a sample. The technique can be optimised to separate out a single protein, 
which can be excised from a gel and characterised using mass spectrometry. The 
technique was first described by O’Farrell (1975) where he separated an Escherichia 
coli sample. O’Farrell proved by reproducibility that proteins migrate to the same spot 
on a gel based on their pH and molecular mass.  
The first dimension is known as isoelectric focusing (IEF) and proteins are separated 
based on their pH. The sample is applied to a gel adhered to a plastic strip. The strip 
has a gradient in the form of carrier ampholytes, across a specified pH range, 
embedded in the gel. The first dimensional strips are rehydrated in a buffer similar to 
the lysis buffer of the sample. The solubilised sample may be mixed with the 
rehydration buffer at this point and be taken up across the gel strip in a passive 
manner, known as ‘in-gel’ rehydration. Alternatively, the samples may be applied post-
rehydration in two ways. Firstly, the sample may be placed in a plastic cup and ‘cup-
loaded’ onto the strip actively, under a current. Secondly, the sample can be introduced 
to the strip via a paper bridge and, again, allow the current to attract the proteins. 
Proteins carry a charge, which is dependent on the pH of their surroundings. When an 
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electric field is applied, proteins with a negative charge will move towards the anode 
becoming less charged as it reaches its pI. Likewise, positively charged proteins will 
move toward the cathode under an applied current. The pI of a protein is reached when 
the charge is zero at a specific pH. This allows the charged proteins in the sample to 
find their respective pI, or isoelectric point, when a charge is applied to the gel.  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) separates 
proteins based on their molecular mass; this is carried out subsequent to isoelectric 
focusing. The focused strip is placed along the top of a slab gel composed of an 
SDS/acrylamide mixture. The proteins must be coated in SDS to give them an overall 
negative charge. Sodium dodecyl sulphate is a detergent and therefore contains 
hydrophobic domains. In solution, the SDS and proteins form complexes. The SDS 
masks the charge of the protein, but applies a negative charge itself. The degree of 
separation in the gel now depends on the size and therefore the molecular mass of 
each individual protein. Prior to SDS-PAGE, the proteins on the strip can be equilibrated 
with DTT to reduce any reformed disulphide bonds in the proteins. The strip is then 
equilibrated with iodoacetamide to react with any residual DTT and to alkylate thiol 
groups on proteins, preventing their reoxidation. The buffer system most commonly 
used is the Tris-glycine method described by Laemmli (1970). A front is formed 
between the negatively charged chloride ions from the Tris-HCl, and glycine, which 
moves more slowly. The high pH of the Tris buffer allows minimal protein aggregation, 
which helps the proteins enter the gel and travel through the pores of the 
polyacrylamide matrix. The larger proteins become retarded by the pore size and 
become retained, while smaller proteins migrate towards the anode within the buffer 
front. A tracking dye of bromophenol blue, a small molecule, migrates along with the 
buffer front and indicates when separation is complete. Gels can then be fixed and 
stained to visualise proteins. 
 
 18 
1.10.3 Western blotting 
Blotting was first described in 1975 (Southern) when DNA was transferred to a 
nitrocellulose membrane. Subsequently, Towbin and colleagues (1979) described a 
method for transferring protein from SDS-PAGE gels. Ten percent polyacrylamide mini 
gels are used for separation of proteins up to approx 200kDa. For detection of larger 
proteins 3% (v/v) gels or gradient 3-10% (v/v) gels are used. As in 2D gel 
electrophoresis, bromophenol blue indicates when separation is complete and gels can 
be fixed and stained. Alternatively, proteins can be electrophoretically transferred from 
the gel matrix to nitrocellulose membrane. The proteins can now be probed with specific 
antibodies. Non-specific sites are blocked with excess milk protein after transfer, 
masking all available sites on the nitrocellulose membrane. A secondary antibody 
labelled with a conjugate binds the protein specific primary antibody and levels of 
fluorescence or colour change can then be quantified to show differences between 
samples. 
1.11 Difference in-gel electrophoresis  
Difference in-gel electrophoresis (DIGE) is a modification of 2D SDS-PAGE whereby 
comparisons of samples can be analysed together on a single gel. Analysing biological 
samples within a gel removes variation found from conducting technical replicates. Two 
protein samples are labelled with cyanine dyes, combined, separated on a gel and 
subsequently imaged using fluorescence software (see Figure 1-7). The cyanine dyes 
used in DIGE have a number of criteria that must be met to ensure reproducibility: (i) 
the dyes must match the charge of the amino acid they are replacing, (ii) the difference 
dyes must have a similar charge to each other and (iii) the dyes must have distinct 
fluorescent spectra (Unlu et al., 1997). Originally, a Cy2 dye was used but was shown 
to alter the proteins mass proportionally greater than the other two cyanine (Cy) dyes. It 
is now commonplace to use only cyanine dyes Cy3 and Cy5. The exception where the 
three-dye system is used applies when analysis of complex human samples is required, 
and the third dye, Cy2, is used for normalisation. In this instance the pooled sample is 
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labelled with the Cy2 dye, leaving differences in expression in sample groups to be 
anaylzed using the structurally similar alternative dyes (Tonge et al., 2001). The dyes 
contain a reactive N-hydroxy succinimidyl ester bound to fluorescence cyanine and 
fluoresce at different wavelengths, Cy3 at λ=550nm and Cy5 λ=650nm due to slightly 
different structures. The dyes themselves are hydrophobic and could cause proteins to 
precipitate prior to entering the gel. To overcome this, minimum labelling is preformed 
at 1-2% of total lysine content (Unlu et al., 1997). CyDyes can detect down to the 
nanogram level making them the most sensitive dyes available. 
 
 
Figure 1-7 DIGE image of separated cardiac muscle  
Shown is a single gel with labelled Cy3, Cy5 and overlay images of 2D gel 
electrophoresis separation of combined normal and dystrophic cardiac muscle. 
 
 
1.12 Visualisation 
There are a number of post separation visualisation methods. A method may be 
chosen for its sensitivity, downstream processing or because it is cheap and 
convenient. Coomassie staining provides a simple and cheap method of staining. 
Neuhoff and colleagues (1985) originally described how Coomassie brilliant blue binds 
to proteins, via basic amino acids, in a hydrophobic manner. This hydrophobicity has 
been further sensitised by the addition of ammonium sulfate so that this mass 
spectrometry-compatible method can detect down to 100ng of protein per spot. Another 
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commonly used stain in the laboratory is silver staining. Many methods have been 
described for this more sensitive stain. Detection down to 1ng of protein may be 
possible, but silver staining has a very limited dynamic range. This becomes an issue 
when separating complex tissue samples. Negative staining occurs on abundant 
protein making quantification difficult. Silver nitrate binds proteins and then the silver 
ions become reduced to metallic silver upon the addition of formaldehyde (Rabilloud et 
al., 1994). If gluteraldehyde is removed from the assay the excised stained proteins can 
be used for future mass spectrometry analysis, but this removes some of the sensitivity 
of silver binding. Fluorescent labelling has shown to be a quantifiable, sensitive and 
have a large dynamic range and can be utilised usually at more expense. The use of 
ruthenium as in the SYPRO ruby dye is mass spectrometry compatible but requires the 
use of fluorescent scanners. 
 
1.13 Identification 
Following on from a quantitative comparative proteomic study, the workflow moves to 
identification of the individual proteins. Two-dimensional electrophoresis can highlight 
changes between groups of samples and subsequent analysis using mass 
spectrometry can provide the amino acid sequences of peptides, which can be used to 
identify a protein from a database. Samples must be digested before being applied to 
an analyser. This can be carried out by in-gel digestion or by electroblotting and 
digestion on a membrane. 
1.13.1 In-gel digestion 
Rosenfeld and colleagues (1992) first described the extraction of proteins from an 
SDS-PAGE gel. As the protein is encased within polyacrylamide, the gel must be 
dehydrated first, to allow the uptake of the trypsin enzyme during the reswelling 
process. The proteins are then digested within the gel and the peptides can be 
extracted and analysed. Shevchenko and colleagues (1996) described a method of 
 21 
successfully sequencing proteins from a silver stained polyacrylamide gel without 
chemical modifications from the silver. Other stains like Coomassie and Ruthenium (II) 
tris bathophenantroline disulfonate (RuBPS), bind the protein via hydrophobic methods 
and are easily removed before digestion.  
1.13.2 Digestion on nitrocellulose 
In situ digestion with trypsin from a nitrocellulose membrane was described by 
Aebersold (1987). This method overcame problems encountered with Edman 
degradation as all amino acids within a sequence of peptides could be cleaved. Trypsin 
degrades specifically at arginine and lysine residues. The trypsin digestion generates 
independent sequence information that can be searched in a protein database. 
Analysing samples run from a 1D SDS-PAGE gel overcomes some of the limitations of 
2D proteomics.  
Proteins are transferred to the membrane via electrostatic interactions and 
hydrophobic binding. The membrane-bound proteins can be directly trypsinated, 
reducing the loss of peptides, as proteins need not be precipitated. Also, mass 
spectrometric identifications have less missed cleavages and better coverage (Luque-
Garcia et al., 2006).  
1.13.3 Electrospray ionisation mass spectrometry 
Electrospray ionisation mass spectrometry (ESI-MS) is the formation of small droplets 
of sample, which ionise, evaporate and pass through a vacuum to an analyser. 
Samples in a formic acid/acetonitrile solution flows into the chamber at 1µL/min. An 
electric field is applied to the tip of the needle and this charges the solvent. The 
emerging drop divides into a fine spray of droplets due to repulsion of charges. 
Residual charge on the drop attracts it to the end wall of the chamber. The temperature 
of the nitrogen gas flowing through the chamber slows the evaporation of the solvent off 
the droplets. The size of the droplets decreases as the solvent evaporates. The 
Rayleigh limit is reached when the surface tension exceeds the charge of the droplet, 
causing it to de-form and produce daughter droplets. This continues until the droplets 
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are small enough that the ions can travel through the nitrogen gas vacuum chamber 
and be passed onto the analyser (Yamashita and Fenn, 1984; Fenn et al., 1989).  
 
1.14 Student’s t-test 
Throughout this project, the Student’s t-test is used to calculate significant difference of 
protein expression between normal tissue and an aged-matched diseased tissue. An 
unpaired Student’s t-test is used to test the significance of the difference between two 
sample means where data collected is random or independent of one another. By 
choosing a probability value of 0.05 within the test, we can say that our data is good 
enough to support a conclusion with 95% confidence. This is acceptable when working 
with biological samples. W.S. Gosset went under the pen name of ‘Student’ while 
working for Guinness Brewery, Dublin and he designed the test to monitor the quality of 
batches of Guinness stout being produced. 
 
1.15 Aims of proposed project 
Duchenne muscular dystrophy is the most frequently inherited neuromuscular 
disorder of childhood. The disintegration of the dystrophin-associated glycoprotein 
complex triggers the initial pathology of muscular dystrophy. Secondary modifications 
leading to alterations in membrane stability, cellular signalling and the regulation of ion 
homeostasis cause the further cellular damage of end-stage fibre degeneration. This 
X-linked muscle disease is extremely progressive with skeletal muscle weakening to 
the extent that patients are wheelchair bound by their second decade and 
degeneration of diaphragm muscles lead to respiratory failure. Physiotherapy and early 
respiratory care intervention has greatly improved the life expectancy of affected boys, 
but at an advanced stage of the disease, most Duchenne patients are suffering cardiac 
failure.  
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Although Duchenne muscular dystrophy is extremely progressive, not all muscles are 
affected in the same way. While limb skeletal muscles are severely weakened, 
subtypes of skeletal muscle, namely laryngeal, extraocular and distal muscles are 
usually spared in Duchenne sufferers.  
The purpose of this study was to carry out proteomic profiling on differentially 
distressed dystrophic muscles. The pathobiochemical steps causing a progressive 
decline in dystrophin-deficient cardiac muscle are not well understood. Therefore, we 
carried out a fluorescence difference in-gel electrophoresis, mass spectrometry, 
immunoblotting, confocal microscopy, one-dimensional gel electrophoresis and ‘on-
membrane’ digestion between normal and dystrophic tissues of the heart and naturally 
protected extraocular muscles in order to establish the global protein expression 
pattern. 
Mass spectrometry combined with highly sensitive difference in-gel electrophoresis 
was used to elucidate changes and identify novel biomarkers in dystrophic tissue and 
antibody probing was used to study the fate of specific groups of proteins. We applied 
one-dimensional electrophoresis and ‘on-membrane’ digestion to observe the fate of 
full-length dystrophin isoform and other proteins, (large complexes, membrane-
associated and low-abundant proteins) which are normally excluded from conventional 
two-dimensional gel electrophoresis. 
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2 Materials and methods 
2.1 Materials 
 
2.1.1 General reagents 
General reagents and chemicals were purchased from Sigma Chemical Company 
(Dorset, UK) and were of reagent/electrophoresis grade, unless stated otherwise.  
Distilled H2O was purified using a Millipore Milli-Q apparatus to obtain milli-Q water 
18MΩ. Protease inhibitors were from Roche Diagnostics (Mannheim, Germany). All 
other chemicals used were of analytical grade and purchased from Sigma Chemical 
Company, Dorset, UK. 
 
2.1.2 1D and 2D gel electrophoresis 
For gel electrophoretic protein separation, analytical grade chemicals and materials; 
Immobilized pH gradient (IPG) strips of pH 4- 7 24cm and pH 6-11 18cm; IPG buffer 
were purchased from Amersham Biosciences/GE Healthcare (Little Chalfont, 
Buckinghamshire, UK), and protein molecular mass markers were purchased from 
Biorad Laboratories (Hemel-Hempstead, Hertfordshire, UK). Ultrapure Protogel 
acrylamide stock and 4x Protogel Resolving Buffer stock solutions were obtained from 
National Diagnostics (Atlanta, GA, USA).  
 
 
2.1.3 Protein staining 
The reversible membrane stain MemCode was purchased from Thermo Fisher 
Scientific (Waltham, MA, USA). CyDye DIGE fluor minimal dyes Cy3 and Cy5 were 
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purchased from Amersham Biosciences/GE Healthcare (Little Chalfont, 
Buckinghamshire, UK). 2D silver stain II kit was from Cosmo Bio Company, (Japan). 
Coomassie Brilliant Blue G-250 was from Perbio Science, (Northumberland,UK). 
 
2.1.4 Mass spectrometry 
Sequencing grade-modified trypsin was purchased from Promega (Madison, WI, 
USA). LC-MS Chromasolv water and formic acid were obtained from Fluka (Milwaukee, 
WI, USA). 
 
2.1.5 Western blotting 
Chemiluminescence substrate was obtained from Roche Diagnostics (Mannheim, 
Germany). Nitrocellulose transfer membrane was purchased from Carl Stuart 
(Whitestown, Dublin 24, Ireland). All secondary antibodies were purchased from 
Chemicon International (Temecula, CA, USA). Table 2-1 lists the antibodies used in 
this study including ordering details. 
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Table 2-1 Antibodies 
List of antibodies used for this project including company and catalogue number, 
antibody specificity, host species, dilutions used for both primary and secondary 
antibodies and its application. Species= Host species; 10= primary; 20= secondary; 
pAb= polyclonal antibody; mAb= monoclonal antibody; WB= Western blotting; CF= 
Confocal microscopy; NC= Novocastra; SGN= Stressgen; SC= Santa Cruz 
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αBCrys  NC  NCL‐a‐BCrys  pAb  Bovine  1:250  Ms  1:1000  WB Adenylate kinase  abcam  ab54824  mAb  Human  1:1000  Ms  1:1000  WB ATP synthase  abcam  ab14730  mAb  Human  1:500  Ms  1:1000  WB 
βDystroglycan  NC  NCL‐b‐DG  pAb  Human  1:50  Ms  1:1000  CF 
βDystroglycan  NC  NCL‐b‐DG  pAb  Human  1:100  Ms  1:500  WB 
Calsequestrin  ABR  MA3 913  pAb  Rabbit  1:1000  Rb  1:2000  WB 
cvHSP  HyTest  PCV60  mAb  Rabbit  1:250  Rb  1:1000  WB 
Desmin  ABR  OMA1‐06002  mAb  Chicken  1:100  Ms  1:1000  CF Desmin  ABR  OMA1‐06002  mAb  Chicken  1:250  Ms  1:1000  WB DJ1 protein  abcam  ab76241  pAb  Human  1:1000  Rb  1:1000  WB Dystrophin Dp427  NC  NCL‐DYS2  mAb  Human  1:10  Ms  1:100  CF 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Dystrophin Dp427  NC  NCL‐DYS2  mAb  Human  1:50  Ms  1:100  WB Fatty acid binding protein FABP3  abcam  ab16915  mAb  Human  1:100  Ms  1:500  WB HSP25  SGN  SPA‐801  pAb  Human  1:500  Ms  1:1000  WB 
HSP60  SGN  SPA‐807  pAb  Human  1:500  Ms  1:1000  WB 
HSP90  SGN  SPA‐835  mAb  Human  1:1000  Rt  1:2000  WB Isocitrate dehydrogenase  abcam  ab36329  pAb  Porcine  1:500  Rb  1:1000  WB Laminin  Sigma  L‐9393  pAb  Mouse  1:1000  Rb  1:1000  WB Myosin heavy chain  Sigma  MF20  mAb  Chicken  1:100  Ms  1:1000  CF Myosin heavy chain slow/cardiac  Sigma  M8421  mAb  Human  1:500  Ms  1:1000  WB Prohibitin  abcam  ab28172  pAb  Human  1:100  Rb  1:1000  CF 
Prohibitin  abcam  ab28172  pAb  Human  1:500  Rb  1:1000  WB 
SERCA1  ABR  MA3 912  mAb  Rabbit  1:1000  Ms  1:2000  WB Succinate dehydrogenase  SC  sc‐27992  pAb  Human  1:50  Gt  1:1000  CF Succinate dehydrogenase  SC  sc‐27992  pAb  Human  1:100  Gt  1:1000  WB Utrophin Up395  SC  sc‐15377  pAb  Human  1:100  Rb  1:250  WB VDAC1  abcam  ab14734  mAb  Human  1:1000  Ms  1:1000  WB 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2.1.6 Immunofluorescence microscopy  
Superfrost Plus positively-charged microscope slides were purchased from Menzel 
Glaesser (Braunschweig, Germany). Optimum cutting temperature (OCT) compound 
was from Sakura Finetek Europe B.V (Zoeterwoude, Netherlands) and p-
phenylenediamine (PPD)-glycerol was purchased from Citifluor Ltd. (London, UK). 
Molecular Probes MitoTracker Red CMXRos dye was obtained from BioSciences Ltd., 
Dun Laoghaire, Ireland. The DNA binding dye diamidino-phenyindole (DAPI) was 
obtained from Sigma Chemical Company (Dorset, UK). Fluorescent secondary 
antibodies Alexa fluor 594 goat anti-rabbit IgG, Alexa fluor 594 goat anti-mouse IgG 
and Alexa fluor 488 mouse anti-goat IgG were from Molecular Probes (Eugene, 
Oregon, USA).  
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2.2 Methods 
 
2.2.1 Dystrophic MDX animal model  
Tissue from C57 control mice and age-matched dystrophic MDX mice were obtained 
through the Bioresource Unit of NUI Maynooth and the Animal House of the Bielefeld 
University, Germany. Animals were kept under standard conditions and all procedures 
were performed in accordance with German and Irish guidelines on the use of animals 
for scientific experiments. Ethics approval for the project was granted from NUI 
Maynooth Biomedical (& Life) Sciences Research Ethics Sub Committee. Mice were 
killed by cervical dislocation and snap frozen. As previously demonstrated by 
immunoblotting, the MDX mouse cohort used in this study lacks the 427 kDa isoform of 
dystrophin (Lohan et al., 2005) . 
 
2.2.2 Preparation of total crude muscle extracts 
For the proteomic profiling of crude muscle extracts, three normal and three age-
matched dystrophic hearts, diaphragm or extraocular muscle (n=2 per pool) were 
separately prepared by washing with distilled water to remove excess blood. Using 
appropriate safety equipment; coat, facemask and cryo-gloves tissue was frozen in 
liquid nitrogen. Subsequent to tissue freezing and excess nitrogen evaporating off, 
grinding using a mortar and pestle pulverized muscle tissue. Ground muscle was 
solubilised in lysis buffer with the ratio 100 mg wet weight to 1ml lysis buffer consisting 
of 9.5M urea, 2% (w/v) CHAPS, 0.8% (v/v) IPG buffer pH3-10, 1% (w/v) DTT and 
protease inhibitors for cardiac samples and 7M urea, 2M thiourea, 4% (w/v) CHAPS, 
2% (v/v) IPG buffer pH4-7, 2% (w/v) DTT and protease inhibitors (Doran et al., 2006b). 
Samples for DIGE analysis were placed in buffer containing only urea, CHAPS and a 
protease inhibitor cocktail. Samples were gently rocked for 30 min, suspensions were 
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centrifuged at 4 0C for 20 min at 20,000g and protein concentration was determined 
using the Bradford assay system (Bradford, 1976).  
 
2.2.3 Fluorescence difference in-gel electrophoretic analysis 
Potential differences in the expression pattern of the soluble proteome from normal 
and MDX muscle were analysed using the fluorescent difference in-gel electrophoretic 
DIGE technique (Viswanathan et al., 2006), as recommended by Karp and Lilley 
(2005). The fluorescent dyes Cy3 and Cy5 were reconstituted as a stock solution of 
1mM in fresh dimethylformamide, then diluted to a 0.2mM solution prior to use. 
Labelling was performed with 200pmols of Cy3 fluor dye per 25µg protein. An internal 
pooled standard of every sample was prepared with the Cy5 fluor. Labelled samples 
were then vortexed and incubated for 30 min on ice in the dark. The reaction was 
quenched with 10mM lysine on ice for 10 min. For isoelectric focusing, pH 6-11 IPG 
strips were rehydrated for 12h in rehydration buffer (8M Urea, 0.5% (w/v) CHAPS, 
0.2% (w/v) DTT and 0.2% (v/v) ampholytes) with the addition of 1.2% (v/v) DeStreak 
rehydration solution (Amersham Biosciences/GE Healthcare, Little Chalfont, 
Buckinghamshire, UK). Sample and equal volumes of lysis buffer (9.5M Urea, 2% (w/v) 
CHAPS, 2% (w/v) DTT and 1.6% (v/v) ampholytes) were added by anodic cup loading. 
For pH4-7 focusing, IPG strips were in-gel rehydrated with sample and equal volumes 
of 2x lysis buffer made up in rehydration buffer. The strips were run on an Amersham 
IPGphor IEF system with the following running conditions: 3500V for 21.3h, a 3500 to 
8000V gradient over 10min, and 8000V for 2h. For first dimension separation in the pH 
6-11 range the following protocol was employed: 80V for 4h, 100V for 2h, 500V for 
1.5h, 1000V for 1h, 2000V for 1h, 4000V for 1h, 6000V for 2h and finally 8000V for 
2.5h. Following isoelectric focusing, the IPG strips were equilibrated for 20min firstly in 
buffer containing 6M urea, 30% (v/v) glycerol, 2% (w/v) SDS, 100mM Tris-HCl, pH 8.8 
with the addition of 100mM DTT and subsequently for 20min in buffer supplemented 
with 0.25M iodoacetamide [49]. Strips were briefly washed in sodium dodecyl sulfate-
containing running buffer (125mM Tris, 0.96M glycine, 0.1% (w/v) SDS) and placed on 
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top of 12.5% (v/v) resolving gels. To seal the strip gels, they were overlaid with the 
above-described running buffer containing 1% (w/v) agarose. The separation of the 
cardiac proteins was carried out in the second dimension by standard SDS 
polyacrylamide gel electrophoresis using the DodecaCell system from Bio-Rad 
Laboratories (Hemel Hempstead, Herts., UK). Slab gels contained 50 µg protein per 
gel. Electrophoresis was carried out overnight for approximately 18 hours in the dark at 
1.5V per 21cm-gel until the Bromophenol Blue tracking dye just ran off the gel. 
 
2.2.4 Protein visualization and data analysis 
Fluorescent CyDye-labelled cardiac and extraocular proteins were visualized using a 
Typhoon Trio variable mode imager form Amersham Biosciences/GE Healthcare (Little 
Chalfont, Bucks., UK). For image acquisition, Cy5- and Cy3-labelled proteins were 
scanned at a wavelength of λ=650nm and λ =550nm, respectively. Photomultiplier tube 
values were optimised so that the volume of the most abundant spot was between 
80,000 and 99,000 when scanned at a resolution of 100µm. This guaranteed that no 
spot would be saturated on the gel, therefore interfering with accurate analysis. The 
Cy3 images were then analysed using Progenesis Samespots software version 3.2.3 
from NonLinear Dynamics (Newcastle upon Tyne, UK) and normalised against their 
corresponding Cy5 image. Gels were aligned to the reference image. Following 
detection of spots, the gels were placed into groups (MDX versus normal) and 
analysed to determine significant differences in 2-D spot abundance. An ANOVA score 
of 0.5 was required for spots to be included in the subsequent analysis. Then principal 
component analysis was verified with changes displaying power of <0.8 being removed 
from the analysis. All remaining changed spots that met the significance criteria were 
visually checked on the aligned gels to ensure feasibility and were subsequently 
identified by LC-MS/MS analysis. 
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2.2.5 Mass spectrometric identification of cardiac and extraocular proteins 
Preparative gels containing 400µg of protein (1:1 MDX to normal) were stained with 
the dye Ruthenium II Bathophenanthroline Disulfonate Chelate (RuBPs) [50]. RuBPs-
stained gels were scanned at a wavelength of λ=550nm using the criteria outlined 
above. Prior to identification via LC-MS/MS technology, 2-D protein spots of interest 
were excised using the automated Ettan spot picker system from Amersham 
Biosciences (Little Chalfont, Bucks., UK). Spots were digested as outlined by 
Shevchenko and colleagues (2006). Briefly, gel pieces were destained before the 
addition of 400ng trypsin per spot, incubated for 30min at 40C before being digested 
overnight at 370C. 100µL of extraction buffer (1:2 v/v of 5% (v/v) formic 
acid/acetonitrile) was added to the peptides and incubated for 15min at 370C. All 
supernantant was then transferred into fresh tubes and extracts were dried down 
completely in a vacuum centrifuge. Peptides were reconstituted in 12µL of 0.1% (v/v) 
formic acid, vortexed, sonicated and the mixture was centrifuged for 20min in cellulose 
spin filter tubes to remove any gel particles. The remaining solution was placed into 
LC-MS vials. Samples were analysed on an Agilent 6340 Ion Trap LC mass 
spectrometer using electrospray ionization (Agilent Technologies, Santa Clara, CA, 
USA) on a 10min gradient of 5-100% (v/v) acetonitrile/0.1% (v/v) formic acid with a 
post run of 1min (Lewis et al., 2010b). Separation of peptides was performed with a 
nanoflow Agilent 1200 series system, equipped with a Zorbax 300SB C18 µm, 4mm 
40nl pre-column. Mobile phases used were A: 0.1% (v/v) formic acid, B: 50% (v/v) 
acetonitrile and 0.1% (v/v) formic acid. Samples (8µl) were loaded onto the enrichment 
column with capillary flow rate set at 4µL/min with a mix of A:B at a ratio of 19:1. 
Elution was carried out with the nano pump flow rate set at 0.6µL/min. Database 
searches were carried out using Mascot MS/MS Ion search. Criterion for each search 
was set at (i) species Mus musculus, (ii) two missed cleavages by trypsin, (iii) variable 
modification: oxidation of methioine, (iv) fixed modification: carboxymethylation of 
cysteines and (v) mass tolerance of precursor ions ±2Da and product ions ±1Da. 
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2.2.6 Immunoblot analysis 
In order to determine the fate of select proteins, 1-D gel electrophoresis, Coomassie 
staining and immunoblotting was performed. Gel electrophoretic separation and 
transfer was carried out with a Mini-Protean II electrophoresis and transfer system from 
Bio-Rad Laboratories (Hemel-Hempstead, Herts, UK). Muscle proteins were 
transferred to nitrocellulose for 70min at 100V and at 40C Blocking of nitrocellulose 
sheets was achieved with a milk protein solution (5% (w/v) fat-free milk powder in 0.9% 
(w/v) NaCl, 50 mM sodium phosphate, pH 7.4) for 1h. Incubation with sufficiently 
diluted primary antibody was carried out overnight with gentle agitation. Nitrocellulose 
sheets were washed and then incubated for 1h with secondary horseradish 
peroxidase-conjugated antibodies, diluted in blocking solution. Immuno-decorated 
bands were visualized by the enhanced chemiluminescence method using 
chemiluminescence substrate (Roche Diagnostics, Mannheim, Germany). 
Densitometric scanning of immunoblots was performed using ImageJ (NIH, Bethesda, 
Maryland, USA). 
 
2.2.7 Immunofluorescence microscopy 
For the localization of nuclei, mitochondria and select marker proteins, confocal 
microscopy was used (Doran et al., 2006b). Normal and dystrophic MDX hearts were 
mounted on cyrocassettes at -20ºC and transverse cryosections of 10µm thickness 
were cut on a Shandon Cryotome (Life Sciences International, Cheshire, UK). Unfixed 
tissue sections were transferred to Superfrost Plus positively-charged microscopy 
slides. For labeling of mitochondria, freshly cut tissue sections were incubated with a 
1:100 diluted solution of MitoTracker Red Chloromethyl-X-Rosamine (CMXRos) dye for 
30 min, briefly washed in phosphate-buffered saline and then immediately examined by 
microscopy (Poot et al., 1996). CMXRos is a well-established lipophilic cationic 
fluorescent dye that is highly specific for mitochondria (Pendergrass et al., 2004) and is 
routinely used to measure mitochondrial function and morphology cell culture and in 
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whole tissues (Chazotte, 2009). For immunofluorescence microscopy, cryosections 
were submersed in blocking solution (0.2% (w/v) bovine serum albumin, 0.2% (v/v) 
Triton X-100, and 2.5% (v/v) goat serum in phosphate-buffered saline) for 30 min, 
followed by incubation with primary antibodies diluted in washing solution (0.2% (w/v) 
bovine serum albumin and 0.2% (v/v) Triton X-100 in phosphate-buffered saline) for 4 
hours. Tissue sections were washed twice for 30 min in above washing solution 
omitting antibodies and then labelled with secondary antibodies for 1 hour, followed by 
repeated washing procedure. In order to determine the number of nuclei in normal 
versus MDX hearts, cardiac tissue sections were labelled with 1 µg/ml 
diamidinophenyindole (DAPI) for 30 min. One drop of p-phenylenediamine (PPD)-
glycerol was applied to the immuno-decorated tissue sections and then coverslips 
carefully placed over the sections, avoiding the introduction of air bubbles. Fluorescent 
labelling patterns were visualised with an Olympus IX81 microscope (Olympus Life and 
Material Science Europe, Hamburg, Germany). 
 
2.2.8 1D gel electrophoresis for subsequent digestion 
Protein samples were separated on 3-12% (v/v) gradient sodium dodecyl sulfate 
polyacrylamide gels and stained with Coomassie Brilliant Blue or transferred to 
nitrocellulose (Ohlendieck et al., 1991). Importantly, gel electrophoresis was carried out 
in the absence of combs so that several centimeter-long horizontal strips of individual 
muscle protein bands could be separated. The successful electrophoretic transfer of 
muscle proteins was evaluated by staining of nitrocellulose membranes with the 
reversible stain MemCode. Individual MemCode-stained bands were cut out for 
subsequent treatment with trypsin. 
 
2.2.9 On-membrane digestion 
Protein bands were excised from membranes, placed in a small plastic tube, 
destained and washed 5 times with distilled water. Nitrocellulose strips were then 
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blocked with 0.5% (w/v) polyvinylpyrrolidone (PVP-40) at 370C for 37 min with gentle 
shaking (Luque-Garcia et al., 2008). Membranes were subsequently washed 5 times 
with distilled water. For digestion, a fresh stock solution of 20µg trypsin in 1.5 ml of 
buffer (1:1 (v/v) 100mM ammonium bicarbonate/10% (v/v) acetonitrile) was prepared. 
Membrane strips were digested overnight at 370C in 100µl trypsin solution 
(Shevchenko et al., 2006). Subsequently, 100µl extraction buffer (1:2 (v/v) 5% (v/v) 
formic acid/acetonitrile) was added to the trypsin-treated membranes and gently 
agitated for 15 min at 370C. All supernatant fractions were placed into fresh plastic 
tubes and peptides dried down by vacuum centrifugation (Doran et al., 2006b). 
Peptides were reconstituted in LC running buffer (0.1% (v/v) formic acid), centrifuged 
for 20min in 22µm cellulose spin filter tubes to remove any membrane particles and 
then aliquoted into LC-MS vials. 
 
2.2.10 Mass spectrometric identification of on-membrane digestion 
Recovered peptides were analysed on an Agilent 6340 LC/MS with a 3D Ion Trap 
configuration (Agilent Technologies, Santa Clara, CA, USA) on a gradient of 5-100% 
(v/v) acetonitrile/ 0.1% (v/v) formic acid for 10 min. Separation of peptides was 
performed with a nanoflow Agilent 1200 series system, equipped with a Zorbax 300SB 
C18 5 µm, 4mm 40nl pre-column and an Zorbax 300SB C18 5 µm, 43 mm x 75 µm 
analytical reversed phase column using the HPLC-Chip technology. Mobile phases 
utilized were A: 0.1% (v/v) formic acid, B: 90% (v/v) acetonitrile and 0.1 % (v/v) formic 
acid. Samples (5µl) were loaded into the enrichment at a capillary flow rate set to 4 
µL/min with a mix of A and B at a ratio 19:1. Tryptic peptides were eluted with a linear 
gradient of 5-70% (v/v) solvent B over 6 min, 70-100% (v/v) for 1 min and 100% (v/v) 
for 1 min with a constant nano pump flow of 0.60mL/min. A 1 min post time of Solvent 
A was used and a blank run injected after each sample injection to remove sample 
carryover. The capillary voltage was set to 2000V. The flow and the temperature of the 
drying gas was 4 L/min and 300ºC, respectively. Identified peptides were utilized to 
determine the protein species present in distinct protein bands. Database searches 
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were carried out with Mascot MS/MS Ion search (Matrix Science, London, UK; NCBI 
database, release 20100212). 
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3 Proteomic profiling of the dystrophin-deficient MDX heart 
reveals drastically altered levels of key metabolic and 
contractile proteins 
3.1 Introduction 
X-linked Duchenne muscular dystrophy represents the most commonly inherited 
neuromuscular disease. Although primarily known as a skeletal muscle wasting 
disease, its progressive degenerative effect on the cardiac muscle is not fully 
understood. Hence, we decided to carry out a comprehensive proteomic study 
involving difference in-gel electrophoresis, on the heart, to attempt to identify some 
biomarkers of this muscle wasting disease.  
The identification of the Duchenne muscular dystrophy gene by Koenig and 
colleagues (1987) lead to the discovery of dystrophin, a membrane cytoskeletal 
protein. The Dystrophin gene located at Xp21 is the largest gene in the human 
genome. It covers 2.4 megabases of the X-chromosome and codes for 3585 amino 
acids. Therefore, it is not surprising that there is a very high mutation rate; with many 
Duchenne patients suffering from deletions in the gene (Moser, 1984) and point 
mutations (Den Dunnen et al., 1989).  
The 427kDa protein is located at the surface membrane of the muscle cell. 
Dystrophin forms part of a large supramolecular complex, which provides stability 
across the membrane and within the cell. In the dystrophic cell the protein is almost 
completely absent from the cell surface (Bonilla et al., 1988). This absence leads to the 
phenotype of muscle weakness and fibre wasting. Most symptoms are due to the 
secondary effects caused by the rupturing of the membrane, alterations in the 
excitation-contraction coupling and ion leakage (Menke and Jockusch, 1991; Emery, 
2002).  
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3.1.1 Duchenne muscular dystrophy and the heart 
Dystrophin is linked to many membrane glycoproteins, making up the dystrophin-
glycoprotein complex (DGC). Although the function of all the membrane spanning 
proteins within the complex are not fully understood, mutations lead to muscular 
dystrophies, lending weight to how important they are in stabilizing and strengthening 
the membrane (Campbell, 1995; Lim and Campbell, 1998). The DGC binds other 
complexes such as calveolin-3 and the integrin complex. These dystrophin-associated 
complexes can recruit proteins and enzymes, facilitate phosphorylation and up-
regulate alternative proteins/kinases activating cell signalling and growth and survival 
pathways (Ahn et al., 1996; Newey et al., 2000; Sotgia et al., 2000). 
There are a number of tissue-specific isoforms of dystrophin, leading to varying 
degrees of severity of tissue damage. Variations of full-length isoforms are found in 
brain, heart and skeletal muscles (Culligan and Ohlendieck, 2002; Lohan et al., 2005). 
Unlike skeletal tissue, cardiac tissue does not undergo degenerative-regeneration 
cycles and the cardiac fibres become replaced by connective and fatty tissue 
(Leferovich et al., 2001). This is brought about by the loss of dystrophin anchoring 
extracellular laminin via the DGC to the cytoskeleton. The membrane becomes 
ruptured by the loss of membrane proteins and calcium channels are used to reinforce 
the gaps. This leads to an influx of calcium ions into the cytoplasm, which becomes 
toxic to the cell, triggering stress responses. Along with structural integrity being lost 
there are the secondary effects of destruction and abnormal calcium handling. 
Excitation-contraction coupling in the heart also takes place at the transverse tubules. 
Therefore physical stresses along this region of the membrane in dystrophic myofibrils 
may exacerbate the cardiac muscular dystrophic phenotype (Knudson et al., 1988).  
Duchenne muscular dystrophy is primarily a skeletal muscle disorder and better 
treatment of the limb and respiratory systems has extended the life expectancy of 
sufferers. Cardiac involvement in muscular dystrophies is now becoming significant 
whereby nearly 20% of DMD and 50% of the milder form Becker muscular dystrophy 
patients are dying from cardiomyopathy by their third decade (Finsterer and 
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Stollberger, 2003). In this study, we are using the established animal model of the X-
linked muscular dystrophy (MDX) mouse. Although missing the Dp427 protein 
dystrophin, it is argued that the MDX mouse does not match the DMD phenotype 
entirely in relation to cardiomyopathies (Bridges, 1986). DMD patients display left 
ventricular (LV) wall abnormalities and lose LV contractile force, whereas many studies 
show mice displaying this hypokinesia throughout the heart muscle. In addition, DMD 
hearts show patchy fibrosis and fatty replacement affecting the LV most, whereas the 
MDX mouse appears not to be affected quite so severely. In saying that, aged studies 
of MDX mice at 9-10 months have shown comparable dystrophic cardiomyopathies to 
DMD patients (Quinlan et al., 2004; Spurney et al., 2008). Mice missing cardiac 
dystrophin begin with normal heart functions but then develop tachycardia, impaired 
contractile properties increase in fibrosis, infiltration of fatty tissue and necrosis 
(Bridges, 1986; Bia et al., 1999; Quinlan et al., 2004). Based on these findings we have 
used a 9-month-old animal to test the proteomic alterations of the diseased heart.  
3.1.2 Proteomics and the heart 
A useful tool within proteomics is the availability of mass spectrometry (MS) to 
identify proteins of interest. Mass spectrometry can be used to identify biomarkers of a 
comparative biomedical study. Identification of markers characterized from diseased 
versus normal animal study is useful in enhancing our knowledge of the disease 
pathways and progression. Coupled with fluorescent dyes, the number of identifiable 
spots from two-dimensional gels has increased so much that fluorescent difference in-
gel electrophoresis (DIGE) and mass spectrometry is considered a sensitive and 
powerful tool. With DIGE being capable of detection down to originally nanogram (Unlu 
et al., 1997) and now femtomole (fmol) quantities (Viswanathan et al., 2006) mass 
spectrometry detection has striven to gain its lowest detection level also. The liquid-
chromatography electrospray ionization mass spectrometer (LC-MS ESI) used during 
this study certainly detects down to fmols of protein. The limitation of this is that 
complex samples are more difficult to detect than purified bovine serum albumin and 
MS running buffers, protocols and sample digestion all play a role in MS sensitivity.  
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DMD patient samples show large variation in expressed proteins and large 
experimental repeats would be needed; therefore inbred genetically homogeneous 
animal models can be more useful in gaining initial insight into disease pathology. The 
fact that animal models usually do not represent perfectly the human pathology of 
diseases adds a limitation to the research. High-throughput proteomic studies means 
that information can be gained quickly and when combined with genomic and 
metabolomic data different models can quickly be assessed for matching tissue-
specific pathology. Proteomic profiling can examine thousands of samples and give 
back information on protein and isoforms abundance and post-translational 
modifications. Recent proteomic data has catalogued the 2D spot pattern of many 
small animal models and shown how similar the distribution of protein markers are to 
human fibre proteome (Sanchez et al., 2001; Yan et al., 2001). Similar workflows have 
then been used to analyze animal tissue to show fibre type shifting (Donoghue et al., 
2005) and glycosylation and phosphorylation due to tissue ageing (O'Connell et al., 
2007; Gannon et al., 2008). Proteomic changes in the heart have been previously 
studied using DIGE and MS. Forner and colleagues (2006) showed the differences in 
mitochondria between heart and skeletal muscle and the proteomic profile of 
contractile dysfunction in a failing heart was studied with respect to the molecular 
mechanisms (Phillips et al., 2010). With respect to X linked muscular dystrophy, 
studies on the MDX skeletal and diaphragm tissues have revealed a number of 
biomarkers involved in abnormal calcium handling, sarcolemmal integrity, necrosis and 
stress responses (Culligan et al., 2002; Doran et al., 2006a; Doran et al., 2006b). 
Dystrophin deficient cardiomyopathy has been investigated by other laboratories using 
genomic and metabolomic studies, their recent findings showed that there were large 
perturbations in the energy producing pathways and mitochondria in cardiac tissue and 
that hormones related to necrosis were up-regulated. In addition, the expression of 
taurine directly related to the increase seen in utrophin in MDX tissue. Taurine has 
previously been correlated with muscle regeneration after necrosis. Transcription levels 
of Nox4, a gene involved in cardiac fibrosis and cell survival were increased five fold in 
aged MDX mice hearts (Gulston et al., 2008; Spurney et al., 2008). Combining these 
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studies with a proteomic investigation into the dystrophic heart may give a more 
detailed knowledge of a primarily genetic disorder that develops a perturbed 
downstream phenotype.  
3.1.3 Experimental design 
To gain insight into the changes occurring in the dystrophic myofibres we decided to 
study crude cardiac muscle. It is hoped that this study may be useful in enhancing 
knowledge about the molecular mechanisms involved in dystrophic heart and that in 
the future it could be used to evaluate drugs or novel therapies affect on the heart. This 
report describes the detailed analysis of DIGE labeled normal and dystrophic cardiac 
MDX tissue. Firstly, their isoelectric point separated the proteins across the ranges of 
pH 4-7 and pH 6-11. In the second dimension, the proteins were separated based on 
their molecular mass. The fluorescently tagged proteins were visualized and 
densitometric measurements determined the expression levels of all spots across all 
gels. Finally, proteins of interest were digested and identified via ESI LC-MS. Changes 
in the protein regulation were then confirmed by immunoblotting and confocal 
microscopy.  
3.2 Results 
DIGE allows the separation of multiple samples within one two-dimensional gel. This 
reduces the artefacts that can be introduced due to gel-to-gel variation. We have 
carried out a comparative proteomic study of 9-month old normal versus age-matched 
MDX mouse heart. The number of mice was kept to a minimum due to the 
considerable cost of maintaining aged mice and the high cost of the fluorescent dyes. 
A two-dye set was chosen because the analysis was being carried out on only two 
sample types and they were inbred mice, so show less genetic variability as opposed 
to complex human samples where a three dye system would be suggested. The 
recommendations of Karp and Lilley (2005) were taken into consideration and three 
biological replicates for each sample type was run. During first separation, isoelectric 
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focusing was carried out over the 4-7 and 6-11 pH ranges to maximize the separation 
of cardiac proteins. Figure 3-1 shows the acidic to neutral proteins separated out over 
a 12% (v/v) SDS-PAGE gel and Figure 3-2 shows the separation of the more basic end 
of the soluble heart proteins. Shown are the representative two-dimensional gels of the 
Cy3 labeled normal muscle (Figure 3-1A; Figure 3-2C), Cy3 labeled MDX muscle 
(Figure 3-1C, Figure 3-2G) and the corresponding Cy5 labeled pooled standards 
(Figure 3-1B;D; Figure 3-2F,G), which were scanned on a Typhoon Trio variable 
imager and analysed using Progenesis SameSpots software. Across the entire pH 
range 2,509 distinct spots were recognized, with 2,048 spots on the pH 4-7 gels and 
487 spots detected on the pH 6-11 range. 79 spots showed a drastic differential 
expression pattern, with 3 proteins being increased and 26 distinct proteins being 
decreased. Electrospray ionization mass spectrometry analysis was carried out to 
identify the cardiac proteins with changes abundance in dystrophic heart tissue. 
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Figure 3-1 2-D DIGE analytical gel of normal versus MDX cardiac muscle in the pH 4-7 range. 
Shown are Cy3-labeled gels of the soluble fraction of crude normal (A) and dystrophic 
MDX (C) cardiac muscle as well as Cy5-labeled gels containing all samples combined 
to form a pooled standard (B, D). Representative fluorescent DIGE gels with 
electrophoretically separated proteins are shown for the pH 4-7 range. The pH-values 
of the first dimension gel system and molecular mass standards (in kDa) of the second 
dimension are indicated on the top and the left of the panels, respectively. 
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 Figure 3-2 2-D DIGE analytical gel of normal versus MDX cardiac muscle in the pH 6-11 range. 
Shown are Cy3 labeled gels of the soluble fraction of crude normal (A) and dystrophic 
MDX (C) cardiac muscle as well as Cy5 labeled gels containing the pooled standards 
(B,D). Representative fluorescent DIGE gels with electrophoretically separated proteins 
are shown for the pH 6-11 range. The pH-values of the first dimension gel system and 
molecular mass standards (in kDa) of the second dimension are indicated on the top 
and the left of the panels, respectively. 
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3.2.1 DIGE analysis of the dystrophin-deficient heart  
A list of the cardiac proteins with significantly altered expression level in the 
dystrophic MDX tissue is shown in Table 3-1. The information on the 79 DIGE 
identified protein spots combines data from both the pH 4-7 and pH 6-11 separations 
and contains protein name, protein ID, number of matched peptides, percentage 
sequence coverage, the relative molecular mass, pI values and Mascot score and fold 
change of individual proteins affected by deficiency in dystrophin. The majority of 
identified cardiac proteins belonged to the main classes of metabolic or contractile 
proteins. Components of the actomyosin apparatus, enzymatic and regulatory 
elements of mitochondria, glycolytic enzymes, metabolic transporters, cellular stress 
proteins and cytoskeletal components were clearly identified by MS analysis. Cardiac 
proteins with a dystrophy-related change in abundance ranged in molecular mass from 
apparent 14 kDa to 90 kDa and covered a pI range from approximately 5 to 9. DIGE 
Cy5 master gels of both the pH 4-7 and pH 6-11 range are shown in Figure 3-3 so that 
it is possible to correlate MS identified protein species, listed in Table 3-1, with distinct 
two-dimensional spots of altered density in the dystrophic heart. An increased 
expression level was shown for 3 cardiac proteins. These are listed as nucleoside 
diphosphate kinase B (spot 1), the nuclear lamina matrix protein lamin A/C (spot 2) and 
a component of the electron-transferring flavoprotein dehydrogenase (spot 3). All other 
identified protein species exhibit decreased abundance in dystrophic-deficient 
myocardial tissue.  These cardiac proteins are marked and numbered 4 to 79 in the 
Cy5 labeled master gels of Figure 3-3. The protein species with the highest decrease 
in concentration was identified as the anti-oxidant enzyme peroxiredoxin-6 (spot 79). In 
addition, mitochondrial ATP synthase (spots 50,55, 69, 72, 74, 77), isocitrate 
dehydrogenase (spots 38, 42), NADH dehydrogenase (spot 40), pyruvate 
dehydrogenase (spots 11, 14, 15, 20, 25, 34), isoveryl-CoA dehydrogenase (spots 8 
and 19), oxoglutarate dehydrogenase (spot 7), prohibitin (spot 6), electron-transferring 
flavoprotein (spot 5, 17, 36), myozenin-2 (spot 4), voltage-dependent anion-selective 
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channel VDAC1 (spot 41), the slow/cardiac isoforms of myosin light chain MLC2 (spots 
26, 48, 62, 65, 70, 78), myosin light chain MLC3 (spots 53, 61, 76), cardiac alpha-actin 
(spots 21, 39, 45, 46, 56, 60, 64, 66, 67, 71, 75), alpha-1 tropomyosin (spots 35, 59), 
adenylate kinase AK1 (spot 68), creatine kinase (spot 16), cytochrome c oxidase 
(spots 22, 51), cytochrome b-c complex (spots 10, 30, 57, 63), desmin (spots 43, 47, 
52, 54, 58), vimentin (spots 12, 23), cardiac fatty acid binding-protein FABP3 (spots 27, 
33, 49), heat shock protein Hsp27 (spot 18), heat shock protein Hsp60 (spots 31, 37, 
44), enolase (spots 13, 28, 32), DJ-1 protein (spot 27), valosin-containing protein VCP 
(spot 24) and albumin (spot 9) were identified. The results for 2 additional decreased 
protein spots have not been included in Table 3-1, since they only contained 1 
matched peptide per cardiac protein as determined by MS analysis. The peptide 
sequences LGANSLLDLVVFGR (2% sequence coverage) and LTFDSSFSPNTGK (4% 
sequence coverage) identified the non-listed cardiac proteins as succinate 
dehydrogenase (73.6 kDa; pI 7.1) and porin isoforms VDAC1 (32.5 kDa; pI 8.6), 
respectively. 
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Table 3-1 List of the DIGE-identified proteins with a changed abundance in 9-month old 
dystrophic MDX heart muscle 
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1 Nucleoside diphosphate kinase B NDKB_MOUSE 4.4 4 34 17.5 7.0 69 
2 Lamin-A/C LMNA_MOUSE 1.9 4 6 74.5 6.5 111 
3 
Electron transfer 
flavoprotein-
ubiquinone 
oxidoreductase, 
mitochondrial 
ETFD_MOUSE 1.8 8 15 68.9 7.3 45 
4 Myozenin-2 MYOZ2_MOUSE -1.5 4 20 29.8 8.5 145 
5 
Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 
ETFA_MOUSE -1.5 2 12 35.3 8.6 89 
6 Prohibitin PHB_MOUSE -1.5 8 41 29.9 5.6 290 
7 
Dihydrolipoyllysine-
residue 
succinyltransferase 
component of 2-
oxoglutarate 
dehydrogenase 
complex, 
mitochondrial 
ODO2_MOUSE -1.6 3 6 49.3 9.1 86 
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8 
Isovaleryl-CoA 
dehydrogenase, 
mitochondrial 
IVD_MOUSE -1.7 7 23 46.7 8.5 89 
9 Serum albumin ALBU_MOUSE -1.7 3 5 70.7 5.8 82 
10 
Cytochrome b-c1 
complex subunit 
Rieske, mitochondrial 
UCRI_MOUSE -1.8 4 13 29.6 8.9 84 
11 
Dihydrolipoyllysine-
residue 
acetyltransferase 
component of 
pyruvate 
dehydrogenase 
complex, 
mitochondrial 
ODP2_MOUSE -1.9 10 20 68.5 8.8 117 
12 Vimentin VIME_MOUSE -1.9 11 20 53.7 5.1 118 
13 Beta-enolase ENOB_MOUSE -2.0 8 19 47.3 6.7 111 
14 
Pyruvate 
dehydrogenase E1 
component subunit 
beta, mitochondrial 
ODPB_MOUSE -2.0 8 31 39.3 6.4 279 
15 
Pyruvate 
dehydrogenase E1 
component subunit 
beta, mitochondrial 
ODPB_MOUSE -2.0 3 19 39.3 6.4 134 
16 Creatine kinase M-type KCRM_MOUSE -2.0 2 4 43.3 6.6 47 
17 
Delta(3,5)-
Delta(2,4)-dienoyl-
CoA isomerase, 
mitochondrial 
ECH1_MOUSE -2.0 4 24 36.4 7.6 201 
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18 Heat shock protein beta-1 Hsp27 HSPB1_MOUSE -2.0 2 8 23.1 6.1 50 
19 
Isovaleryl-CoA 
dehydrogenase, 
mitochondrial 
IVD_MOUSE -2.0 7 17 46.7 8.5 98 
20 
Pyruvate 
dehydrogenase 
protein X component, 
mitochondrial 
ODPX_MOUSE -2.1 5 11 54.3 7.6 63 
21 Actin, alpha cardiac muscle 1 ACTC_MOUSE -2.1 6 19 42.3 5.2 104 
22 
Cytochrome c 
oxidase subunit 5B, 
mitochondrial 
COX5A_MOUSE -2.1 2 14 14.1 8.7 52 
23 Vimentin VIME_MOUSE -2.1 13 27 53.7 5.1 122 
24 
Transitional 
endoplasmic reticulum 
ATPase (valsolin-
containing protein) 
TERA_MOUSE -2.2 5 10 90.0 5.1 171 
25 
Pyruvate 
dehydrogenase E1 
component subunit 
beta, mitochondrial 
ODPB_MOUSE -2.3 4 14 39.3 6.4 100 
26 
Myosin regulatory 
light chain 2, 
ventricular/cardiac 
muscle isoform 
MLRV_MOUSE -2.3 9 52 18.9 4.9 209 
27 Fatty acid-binding protein, heart FABPH_MOUSE -2.3 5 37 14.8 6.1 149 
28 Alpha-enolase ENOA_MOUSE -2.3 2 3 47.5 6.4 43 
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29 Protein DJ-1 PARK7_MOUSE -2.3 4 26 20.2 6.3 90 
30 
Cytochrome b-c1 
complex subunit 1, 
mitochondrial 
QCR1_MOUSE -2.3 6 17 53.4 5.8 83 
31 60 kDa heat shock protein, mitochondrial CH60_MOUSE -2.4 2 6 61.1 5.9 63 
32 Beta-enolase ENOB_MOUSE -2.4 3 7 47.3 6.7 92 
33 Fatty acid-binding protein, heart FABPH_MOUSE -2.4 7 52 14.8 6.1 162 
34 
Pyruvate 
dehydrogenase 
protein X component, 
mitochondrial 
ODPX_MOUSE -2.4 2 4 54.3 7.6 66 
35 Tropomyosin alpha-1 chain TPM1_MOUSE -2.5 15 43 32.7 4.7 302 
36 
Electron transfer 
flavoprotein subunit 
alpha, mitochondrial 
ETFA_MOUSE -2.5 8 33 35.3 8.6 235 
37 60 kDa heat shock protein, mitochondrial CH60_MOUSE -2.5 12 32 61.1 5.9 346 
38 
Isocitrate 
dehydrogenase [NAD] 
subunit alpha, 
mitochondrial 
IDH3A_MOUSE -2.5 9 29 40.1 6.3 164 
39 Actin, alpha cardiac muscle 1 ACTC_MOUSE -2.6 12 31 42.3 5.2 317 
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40 
NADH 
dehydrogenase 
[ubiquinone] 
flavoprotein 2, 
mitochondrial 
NDUV2_MOUSE -2.6 6 29 27.6 7.0 370 
41 
Voltage-dependent 
anion-selective 
channel protein 1 
VDAC1_MOUSE -2.6 10 29 32.5 8.6 292 
42 
Isocitrate 
dehydrogenase [NAD] 
subunit alpha, 
mitochondrial 
IDH3A_MOUSE -2.6 13 39 40.1 6.3 376 
43 Desmin DESM_MOUSE -2.6 30 50 53.5 5.2 1184 
44 60 kDa heat shock protein, mitochondrial CH60_MOUSE -2.7 25 38 61.1 5.9 842 
45 Actin, alpha cardiac muscle 1 ACTC_MOUSE -2.8 10 26 42.3 5.2 276 
46 Actin, alpha cardiac muscle 1 ACTC_MOUSE -2.8 4 14 42.3 5.2 88 
47 Desmin DESM_MOUSE -2.8 15 37 53.5 5.2 349 
48 
Myosin regulatory 
light chain 2, atrial 
isoform 
MLRA_MOUSE -2.8 9 57 19.6 4.8 299 
49 Fatty acid-binding protein, heart FABPH_MOUSE -2.9 12 61 14.8 6.1 425 
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50 
ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE -2.9 18 40 56.3 5.2 1093 
51 
Cytochrome c 
oxidase subunit 5A, 
mitochondrial 
COX5A_MOUSE -2.9 7 28 16.3 6.1 286 
52 Desmin DESM_MOUSE -2.9 26 62 53.5 5.2 1657 
53 Myosin light chain 3 MYL3_MOUSE -2.9 6 41 22.5 5.0 90 
54 Desmin DESM_MOUSE -3.0 12 30 53.5 5.2 431 
55 
ATP synthase 
subunit d, 
mitochondrial 
ATP5H_MOUSE -3.0 3 21 18.8 5.5 48 
56 Actin, alpha cardiac muscle 1 ACTC_MOUSE -3.1 16 40 42.3 5.2 598 
57 
Cytochrome b-c1 
complex subunit 1, 
mitochondrial 
QCR1_MOUSE -3.1 12 27 53.4 5.8 330 
58 Desmin DESM_MOUSE -3.1 36 68 53.5 5.2 1289 
59 Tropomyosin alpha-1 chain TPM1_MOUSE -3.1 21 46 32.7 4.7 605 
60 Actin, alpha cardiac muscle 1 ACTC_MOUSE -3.2 18 59 42.3 5.2 450 
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61 Myosin light chain 3 MYL3_MOUSE -3.3 11 63 22.5 5.0 231 
62 
Myosin regulatory 
light chain 2, 
ventricular/cardiac 
muscle isoform 
MLRV_MOUSE -3.4 13 73 18.9 4.9 118 
63 Cytochrome b-c1 complex subunit 1 QCR1_MOUSE -3.4 12 31 53.4 5.8 342 
64 Actin, alpha cardiac muscle 1 ACTC_MOUSE -3.5 7 36 42.3 5.2 160 
65 
Myosin regulatory 
light chain 2, 
ventricular/cardiac 
muscle isoform 
MLRV_MOUSE -3.5 7 46 18.9 4.9 354 
66 Actin, alpha cardiac muscle 1 ACTC_MOUSE -3.6 4 24 42.3 5.2 91 
67 Actin, alpha cardiac muscle 1 ACTC_MOUSE -3.7 17 62 42.3 5.2 294 
68 Adenylate kinase isoenzyme 1 KAD1_MOUSE -3.8 5 31 21.6 5.7 174 
69 
ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE -3.8 4 21 56.3 5.2 92 
70 Myosin regulatory light chain 2 MLRA_MOUSE -3.9 6 47 19.6 4.8 168 
71 Actin, alpha cardiac muscle 1 ACTC_MOUSE -3.9 18 61 42.3 5.2 302 
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72 
ATP synthase 
subunit d, 
mitochondrial 
ATP5H_MOUSE -3.9 5 36 18.8 5.5 69 
73 
ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE -3.9 18 51 56.3 5.2 640 
74 
ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE -3.9 25 71 56.3 5.2 1102 
75 Actin, alpha cardiac muscle 1 ACTC_MOUSE -3.9 6 16 42.3 5.2 119 
76 Myosin light chain 3 MYL3_MOUSE -4.0 6 30 22.5 5.0 99 
77 
ATP synthase 
subunit beta, 
mitochondrial 
ATPB_MOUSE -4.1 24 70 56.3 5.2 871 
78 myosin light chain 2, ventricular/cardiac MLRV_MOUSE -4.1 11 77 18.9 4.9 206 
79 Peroxiredoxin-6 PRDX6_MOUSE -5.3 3 19 25.0 5.7 102 
 
* The Mascot score has a 95% confidence level if >20
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Figure 3-3 DIGE analysis of 
normal versus dystrophic 
MDX cardiac muscle  
Shown are the pooled 
sample Cy5-labeled 
master gels of the soluble 
fraction from murine 
heart. The map covers 
the pH 4-7 (A) and pH 6-
11 (B) ranges. Protein 
spots with significantly 
changed expression 
levels are marked by 
circles and numbered 1 -
79. See Table 3-1 for a 
detailed listing of the 
identified cardiac proteins 
with a change in 
abundance in the 
dystrophic phenotypic 
tissue. The pH-values of 
the first dimension gel 
system and molecular 
mass standards (in kDa) 
of the second dimension 
are indicated on the top 
and the left of the panels, 
respectively.  
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3.2.2 Decreased proteins in dystrophic heart muscle 
Examples of key cardiac proteins with a significantly decreased expression in 
dystrophic fibres are shown as enlarged images of DIGE-identified protein spots in 
Figure 3-4. Minimal labelling allows for direct comparison of fluorescence-labeled 2D 
protein spots which have been unequivocally identified by mass spectrometric analysis 
(Table 3-1). Shown are the mitochondrial proteins ATPase synthase, porin isoform 
VDAC1, isocitrate dehydrogenase, succinate dehydrogenase and prohibitin as well as 
DJ-1 protein, the stress protein Hsp60 and myosin light chain isoforms MLC2. Figure 
3-5 shows additional enlarged images of DIGE-identified proteins of the cytosolic AK1 
isoform of adenylate kinase and metabolitic cardiac isoform FABP with corresponding 
examples of 3D images. A large proportion of the cardiac proteins identified in this 
study by DIGE analysis belong to the contractile apparatus, the cellular stress 
response and the cytoskeletal network, as well as mitochondrial metabolism including 
oxidative phosphorylation, the citric acid cycle and fatty acid transportation. 
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Figure 3-4 Decreased expression of key proteins in the dystrophic-deficient MDX heart 
Shown are expanded views of 2D gels of normal versus dystrophic MDX heart tissue. 
Shown are ATP synthase, DJ-1 protein, porin isoform VDAC1, stress protein Hsp60, 
isocitrate dehydrogenase (IDH), myosin light chain MLC2, succinate dehydrogenase 
(SDH) and prohibitin.  
 
 
 
 
Figure 3-5 Decreased expression of key proteins with 3D comparative images 
Shown are the expanded views of 2D gels of normal versus dystrophic MDX heart 
tissue with matching 3D views of AK1 isoform of adenylate kinase and fatty acid 
binding protein FABP3. 
 58 
3.2.3 Immunoblot analysis of dystrophic heart muscle 
We employed Western blotting here to verify the results from our DIGE analysis by 
immunoblotting a selected group of cardiac proteins. At this point, it is important to 
state that mass spectrometry-based proteomic analysis is of individual 2D spots 
excised from an SDS-PAGE gel and therefore one can isolate isoforms of a particular 
protein. 1D immunoblotting or immunohistochemistry may not be capable of separating 
isoforms due to lack of antibody specifity. Our analysis shows that many isoforms of a 
particular protein appear in the gel but that not all isoforms may hold the same fate 
and, as we have found, proteomic findings from biochemical or cell biological analysis 
of total protein often does not correlate fully with individual 2D spots. Figure 3-6 shows 
Coomassie stain 1D gel and an equally loaded immunoblot of laminin of crude 
preparations from normal and dystrophic heart tissue and it illustrates that no major 
differences exist in the overall protein expression levels between the two different 
phenotypes. Figure 3-7 shows immunoblot analysis and relates to the combination of 
all isoforms of cardiac desmin in total crude tissue and is found not to be significantly 
different. The analysis of mitochondrial marker proteins (Figure 3-8) shows that the 
majority of the energy production mitochondrial components are drastically down-
regulated. This holds for ATP synthase, porin isoform VDAC1, the fatty acid transporter 
protein cardiac fatty acid binding protein FABP3, isocitrate dehydrogenase IDH and 
succinate dehydrogenase SDH. Shown in the stress regulatory protein analysis figure 
(Figure 3-9) are the immuno-decorated bands of antibodies to Hsp60 and DJ1. The 
statistical analysis shows neither of these proteins to be significantly decreased in 
expression between normal and dystrophic preparations. Thus the overall isoform 
population of Hsp60 and DJ1 does not appear to be reduced in dystrophinopathy, 
although the above-described DIGE analysis showed a lower level of distinct sub-
species of these cardiac elements. In general, the immunoblotting results support the 
main findings from our DIGE analysis of normal versus dystrophic heart tissue and 
demonstrate independently that the deficiency in dystrophin has a profound effect in 
the expression pattern of the cardiac protein complement.   
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  Figure 3-6 Immunoblotting survey of equally loaded cardiac tissue  
Shown is a Coomassie-stained gel (A) of normal and MDX tissue showing equal loading and an 
immunoblot of Laminin (B) an unchanged protein in dystrophic myofibres shown not to be significantly 
between normal and dystrophic preparations. The comparative blotting was statistically evaluated 
using as unpaired Student’s t-test (n=3 replicates). Error bars represent standard deviation. Lanes 1 
and 2 represent normal and dystrophic muscle extracts from control and MDX mice, respectively. 
 
 
Figure 3-7 Immunoblot analysis of filament protein 
Shown is the cytoskeletal marked protein desmin from crude total extract of normal and MDX 
tissue with graphical presentation of the statistical evaluation. The expression of desmin was 
found not to be significantly different between normal and dystrophic preparations. The 
comparative blotting was statistically evaluated using as unpaired Student’s t-test (n=3 
replicates). Error bars represent standard deviation. Lanes 1 and 2 represent normal and 
dystrophic muscle extracts from control and MDX mice, respectively.  
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Figure 3-8 Immunoblotting survey of cardiac mitochondrial proteins in dystrophic tissue 
Shown are the immunoblots with graphical presentation of the statistical evaluation of 
immuno-decoration using antibodies to ATP synthase (A), porin isoform VDAC1 (B), 
fatty acid binding protein FABP3 cardiac isoform (C), isocitrate dehydrogenase IDH 
(D), succinate dehydrogenase SDH (E) and adenylate kinase AK1 (F). The 
comparative blotting was statistically evaluated using as unpaired Student’s t-test 
(n=3;?p<0.05,??p<0.01). Error bars represent standard deviation. The concentration of 
succinate dehydrogenase was found not to significantly different between normal and 
dystrophic preparations. Lanes 1 and 2 represent normal and dystrophic muscle 
extracts from control and MDX mice, respectively. 
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Figure 3-9 Immunoblot analysis of cardiac stress regulatory proteins 
Shown are the immuno-decorated bands of altered expression stress regulation 
proteins in dystrophin-deficient myofibres. The comparative blotting was statistically 
evaluated using an unpaired Student’s t-test (n=3; ?p<0.05). Error bars represent 
standard deviation. Lanes 1 and 2 represent normal and dystrophic muscle extracts 
from control and MDX mice, respectively. The concentration of crude total cardiac 
Hsp60 and DJ1 was found to have opposite fate to the DIGE analysis, where a number 
of isoforms of both proteins shown were down-regulated. 
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3.2.4 Immunofluorescence microscopy analysis of dystrophic heart muscle 
Since the DIGE analysis of the normal versus the dystrophic MDX heart has revealed 
changes in a variety of mitochondrial components, it was important to determine 
whether this alteration was due to a reduction in the number of mitochondria. Figure 
3-10 shows representative results from a mitochondrial stain marker, a zoom view with 
nuclei and survey of nuclei number. DAPI staining revealed 229±6 and 270±18 nuclei 
per examined tissue section in normal versus dystrophic sections, respectively (Figure 
3-10E,F). The slight increase in MDX preparations was not statistically significant 
(n=4). Thus, the proteomic finding of a dystrophic-dependent increase in lamin-A/C is 
therefore not directly related to a drastic change in the number of nuclei per cardiac 
tissue unit. Fluorescent labelling of mitochondria with the MitoTracker dye CMXRos 
showed a characteristic internal staining pattern in cardiac fibres (Figure 3-10A-D). The 
intensity values of fluorescing mitochondrial bundles measured at 1470±36 and 
1384±40 for normal versus MDX preparations and were found not to be significantly 
different (n=4). Hence, lower levels of mitochondrial enzymes do not seem to be a 
consequence of a drastic decrease in mitochondrial density in the dystrophic MDX 
heart. Cryosections of MDX tissue showed a complete absence of the dystrophin 
isoform Dp427 (Figure 3-11A-D), a down-regulation of the sarcolemmal marker ß-
dystroglycan (Figure 3-11E-H) and an unchanged concentration in the slow/cardiac 
myosin heavy chain (Figure 3-11I-L) protein. In addition, confocal microscopy was 
employed for the localization of cardiac mitochondrial marker proteins. The 
immunofluorescence labelling of desmin (Figure 3-12A-D), succinate dehydrogenase 
(Figure 3-12E-H) and prohibitin (Figure 3-12I-L) appear to be comparable between 
normal and dystrophic tissue cryosections. The microscopical localization study 
revealed similar bundling patterns as the mitochondria staining dye but no decrease of 
these proteins in the dystrophic tissue sections, as found by DIGE analysis. This, like 
immunoblotting, indicates although distinct sub-species of certain cardiac proteins are 
affected in linked muscular dystrophy as determined by mass-spectrometry-based 
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proteomics, the overall isoform complement of these elements is not drastically altered. 
This indicates that no major differences exist in the expression levels of desmin-
containing intermediate filament structures and the population of cardiac mitochondria 
in normal versus dystrophin-deficient cells. 
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Figure 3-10 Immunofluorescence survey of mitochondrial content and nuclei number in 
dystrophic cardiac tissue 
Confocal microscopy was used for the localization of mitochondria and nuclei in 
normal (A, C, E) and dystrophic MDX (B, D, F) heart cryosections. Shown is the 
labelling of nuclei with the DNA binding dye DAPI (E, F) and the visualization of 
mitochondria with the red-fluorescent MitoTracker dye CMXRos (A, B), with an overlay 
image of both dyes showing a zoom view of mitochondria and nuclei in selected cells 
(C, D). Graphical presentation of the statistical evaluation of fluorescence intensity of 
the mitotracker dye and nuclei number is shown using an unpaired Student’s t-test 
(n=4). Bar in panels A to F equals 30µm. 
 65 
 
 
Figure 3-11 Immunofluorescence survey of cardiac marker proteins in dystrophic cardiac tissue 
Confocal microscopy was used for the localization of cellular dystrophic markers in 
normal (A, E, I, C, G, K) and dystrophic (B, F, J, D, H, L) heart cryosections. Shown is 
labelling with fluorescent antibodies to full-length dystrophin isoform Dp427 (A-D), ß- 
dystroglycan ßDG (E-H) and myosin heavy chain (MHC) (I-L). White arrowhead marks 
a nuclei and white arrow marks the cell membrane. Bar in panels A to L equals 30µm 
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Figure 3-12 Immunofluorescence survey of cardiac mitochondrial marker proteins in dystrophic 
cardiac tissue 
Confocal microscopy was used for the localization of mitochondrial dystrophic 
markers in normal (A, E, I, C, G, K) and dystrophic (B, F, J, D, H, L) heart cryosections. 
Shown are labelling of antibodies to full-length dystrophin isoform desmin Des (A-D), 
succinate dehydrogenase SDH (E-H) and prohibitin Pro (I-L). Bar in panels A to L 
equals 30µm 
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3.3 Discussion 
Protein expression profiling was used to analyze protein expression of normal and 
diseased cardiac tissue to elucidate markers of linked muscular dystrophy. We wish to 
enhance our knowledge of the molecular pathogenesis of cardiomyopathy of the 
dystrophic heart. Separation, identification and characterization of biomarkers are 
important for (i) the progress of improved diagnostic methods, (ii) the development of 
better therapies to address the secondary affects of the loss of dystrophin, and (iii) the 
evaluation of novel therapeutic methods for the correction of the primary abnormality of 
cardiac dystrophinopathy (Seow et al., 2000). Proteomic profiling is routinely used to 
test the effects and side effects of possible drugs, as published recently by Colussi and 
colleagues (2010) looking for biomarkers of muscle regeneration in an MDX mouse. 
Other MDX protein expression studies look at the protein profiles of double knockout 
mice to give additional insight into the compensatory mechanisms involved in 
dystrophic mice, which furthers our knowledge on possible therapeutic methods (Li et 
al., 2009). Again, the proteomic profiling of MDX skeletal muscle has recently 
established altered expression levels of soluble proteins involved in nucleotide 
metabolism, Ca2+-handling and the cellular stress response (Ge et al., 2003; Doran et 
al., 2004). Mass spectrometry analysis was subsequently carried out on similar 
biochemical samples that were subjected to experimental exon skipping therapy. The 
treatment revealed a partial reversal of dystrophic changes by the change in 
expression of previously identified biomarkers (Doran et al., 2009), demonstrating the 
potential of proteomic technologies to decisively enhance the capabilities of 
biochemical research into the molecular mechanisms that underlie the pathogenesis of 
diseases. In contrast to skeletal dystrophinopathies, little is known about the molecular 
pathogenesis that leads to the cardiac complications of the dystrophin-deficient animal. 
Here, we have successfully applied the fluorescent DIGE method to the large-scale 
analysis of the dystrophic heart. We divided the experiment into two pH ranges, to 
obtain enhanced separation, in an attempt to gain further insights into the down-stream 
 68 
effects of the loss of dystrophin on cardiac tissue. MS-based proteomics clearly 
revealed a drastic decrease in proteins belonging to the contractile apparatus, the 
energy production pathways, cellular stress response and cytoskeletal proteins. Figure 
3-13 displays the divisions in the functions of the identified proteins of the dystrophic 
heart as compared to normal muscle.  
 
 
 
Figure 3-13 Overview of biological functions of DIGE-identified proteins with an altered 
expression in dystrophic heart muscle  
Shown are the apparent functions of DIGE-identified proteins with a significantly 
different expression in normal versus dystrophic-deficient MDX cardiac tissue. A large 
portion of these proteins are involved in contraction of the muscle and mitochondrial 
metabolic proteins including elements of oxidative phosphorylation, the citric acid cycle 
and fatty acid metabolism.  
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3.3.1 Drastically increased concentration of proteins by DIGE analysis 
The DIGE analysis presented has shown a significant increase in lamin-A/C, a 
nuclear lamin. This intermediate filamentous protein is a component of the cytoskeleton 
of the inner nuclear membrane and may provide chromatin stability leading to gene 
expression in the heart. Comparative DAPI staining of nuclei numbers in normal versus 
dystrophic heart cryosections indicated no significant increase in nuclei numbers in 
dystrophin-deficient tissue, therefore, the increase in this lamin protein is due to the 
disease pathogenesis rather than an increase in nuclei. 
The largest increase in concentration of a protein was identified as a 4-fold change in 
expression of nucleoside diphosphate kinase (NDK) B. Nucleoside diphosphate 
kinases are regulatory enzymes involved in the transport of phosphate groups and are 
involved in homeostasis of intracellular di- and tri-phosphonucleosides.  Additionally, 
NDKB has been identified to carry out transcriptional activation and to bind DNA 
(Kimura et al., 2000). These kinases’ functions are implicated in cell growth and 
proliferation, differentiation and signal transduction, which suggests that this up-
regulation may be involved in compensating the severely stressed dystrophin-deficient 
heart myofibres. Another up-regulated protein was an isoform of the electron transfer 
flavoprotein dehydrogenase. Other DIGE-identified proteins involved in electron 
transferring in oxidative phosphorylation and fatty acid metabolism show a decrease in 
protein expression, showing how complex the molecular mechanisms are in a human 
disease and shows the importance of using animal models to reveal changes in protein 
expression. The majority of our protein profiling analysis showed a massive decrease 
in a diversity of cardiac proteins. Many different cellular pathways and range of 
functions are affected in dystrophin-deficient heart cells and our analysis is consistent 
with the severity of cardiomyopathic complications seen in MDX mice and DMD 
patients (Durbeej and Campbell, 2002; Finsterer and Stollberger, 2003). 
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3.3.2 Drastically decreased concentration of protein by DIGE analysis 
Proteins involved with the cardiac contractile apparatus, oxidative phosphorylation, 
nucleotide metabolism, transcription, fatty acid transportation and structurally important 
skeletal proteins were affected by the deficiency of dystrophin in the heart cells. Braun 
and colleagues (2001) could show that MDX slow-twitch tissues are affected in their 
ability to transfer energy via the ATPases in the mitochondria. The altered transfer of 
ATP energy to the mitochondria may contribute to the phenotypic muscle weakness in 
MDX mice and therefore DMD patients. The disturbance in the energy transfer in 
dystrophic tissue can lead to oxidative stress in the cells. Our DIGE study identified the 
largest decrease in expression to be the 6-fold decrease in peroxiredoxin-6, an 
antioxidative enzyme that protects the cell against oxidative stresses. This drastic 
decrease may have severe effects on how the cardiac cell counteracts the detrimental 
stressors.  Many other cellular stress response proteins have also found to be 
decreased in the dystrophic heart tissue, including the small heat shock protein Hsp27 
and Hsp60 as well as DJ-1. Small heat shock proteins act as chaperones, helping the 
cell maintain homeostasis by assisting in protein folding and transporting dysfunctional 
proteins around the cell and they are up-regulated in the heart following exercise 
(Boluyt et al., 2006). Mutations in the DJ-1 protein cause neurodegenerative diseases 
and has been implicated in oxidative stress response and in transcriptional regulation 
(Chen et al., 2010). An impaired stress response could then lead to a detrimental 
aggregation of misfolded proteins and oxidative damage occurring within the dystrophic 
heart cell leading to dysfunction and muscle weakness. The dystrophinopathy-related 
decrease in endoplasmic reticulum ATPase might impair cardiac function as the 
valsolin containing protein is involved in several cellular pathways such as membrane 
fusion and cell-cycle control.  
3.3.3 Decreased concentration of cytoskeletal proteins 
The DIGE analysis presented here of the MDX heart clearly displays an altered 
protein expression of many important members of the cytoskeletal network. Dystrophin 
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is involved in anchoring numerous proteins in and around the membrane. This allows 
the connection of contractile proteins to the membrane, which provides the force 
against which the myosin pulls and permits the muscle to contract. In contrast to 
comparable myosin heavy chain concentrations between normal and dystrophic 
muscle, other critical contractile proteins are negatively affected by the loss of 
dystrophin. The thick and thin filaments of the contractile unit are formed from a 
complex arrangement of myosin. Myosin arrangement is such that two heavy chains 
form a dimer and two pairs of myosin light chains strengthen the ‘lever arm’ that pulls 
against the actin. Mutations in myosin light chains have been implicated in familial 
hypertrophic cardiomyopathy (Szczesna, 2003). Therefore, the reduction in the 
ventricular and atrial isoforms of myosin light chain, and cardiac alpha-actin might have 
a severe impact on the contractile apparatus in the dystrophic heart. Arrhythmias, 
contractile dysfunction and lower heart rates which are observed in dystrophic cardiac 
muscle, could be directly related to the altered concentration of myosin light chains and 
actin (Quinlan et al., 2004). Cardiac cells are activated by calcium binding to 
tropomyosin, in the thin filament, which alters the conformation of actin, allowing a 
cross bridge to form. The observed 3-fold decrease in the tropomyosin alpha-1 chain 
isoform in MDX heart may also be of significant pathophysiological consequence. This 
alteration in myosin and actin concentrations represents a significant structural change, 
which may impair function during sliding of the thick and thin filaments, leading to 
impaired sarcomeric shortening.  
3.3.4 Decreased expression level of intermediate filament proteins 
A reduction was seen in the DIGE analysis of a number of intermediate filament (IF) 
proteins. IF proteins are important for the structural integrity of the muscle cell; they 
help provide elasticity within the contracting fibres. Our proteomic study provided 
information that a number of isoforms of desmin were reduced in expression, but this 
was not confirmed by either immunoblotting or confocal microscopy, which showed the 
overall population of desmin to be unchanged in crude soluble cardiac tissue. However, 
other IF proteins were shown to be down-regulated between normal and MDX heart 
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tissue. Myozenin-2 and vimentin appeared to be reduced in MDX cardiac tissue. A 
mutation of the sarcomeric protein myozenin-2, has shown to cause cardiac 
hypertrophy and arrhythmias (Osio et al., 2007). Vimentin protein coils around itself to 
form a sheet-like structure and provides structural stability to nuclei, endoplasmic 
reticulum and mitochondrial membrane (Herrmann and Aebi, 2004). The abnormal 
expression levels of these proteins might therefore cause a disrupted interfilament 
interaction and an impaired cytoskeletal matrix, thereby causing cellular instability in 
the dystrophic heart.  
3.3.5 Decreased concentration of mitochondrial proteins as identified by DIGE 
analysis 
A significant finding as a part of this study was the drastically reduced concentration 
of numerous mitochondrial proteins and metabolic transporter proteins. Mass 
spectrometry analysis noted a reduction in many proteins belonging to the oxidative 
phosphorylation pathway, the citric acid cycle, glycolysis and fatty acid metabolism. As 
energy production is centred on the massive numbers of mitochondria in the heart, a 
reduction in these elements will have a profound effect on the bioenergetic status of the 
dystrophic heart. Many complex processes are involved in production of ATP in the 
heart. Hydrogen ions are built up outside the mitochondrial membrane, usually donated 
from pyruvate dehydrogenase and NADH, via glycolysis and the citric acid cycle. The 
protons then pass through the electron chain transport system and into the 
mitochondrial membrane spanning enzyme complex ATP synthase. Here oxidative 
phosphorylation occurs using oxygen to convert ADP into the high-energy protein ATP 
that accumulates inside the mitochondria (Lemieux and Hoppel, 2009). This energy is 
then transported throughout the cell including to the contractile filaments and used to 
power the cross-bridge action that ultimately causes the overlap of the thick and thin 
filaments and generates sarcomeric shortening. Previous studies of the dystrophic 
heart have shown that the reduction in intermediate filaments results in a disorganized 
sarcomere and a lower affinity of the mitochondria to ADP and that the dystrophic heart 
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displays disturbances of oxidative phosphorylation (Dunn et al., 1993; Dupont-
Versteegden et al., 1994). Cardiac mitochondria also regulate signalling pathways by 
providing surface receptors to the cytosolic proteins and also allow exchange of solutes 
into the matrix of the mitochondria. Concentrations of cytochrome c found in the 
mitochondrial intermembrane along with adenylate kinase and creatine kinase 
enzymes play a role in cell apoptosis (Benz and Brdiczka, 1992). In the dystrophin-
deficient heart evidence was provided that creatine kinase coupling to oxidative 
phosphorylation was impaired (Braun et al., 2001). Altered expression levels of 
mitochondrial proteins have previously been shown to affect many aspects of normal 
development, diseases and exacerbate the aging process (O'Connell et al., 2007). The 
dysfunction has lead to many forms of heart failure including ischemic reperfusion 
injury (Rouslin, 1983) and dilated cardiomyopathy (Liao et al., 1996). Therefore, a 
reduced concentration of many mitochondrial proteins associated with the outer and 
inner membrane, intermembrane and matrix suggests an impaired metabolism in the 
dystrophic heart. Reduced expression within the mitochondrial proteome appears to 
affect functioning of ATP synthase, creatine kinase, adenylate kinase, cytochrome b-c 
complex, ER ATPase, NADH dehydrogenase, oxoglutarate dehydrogenase, pyruvate 
dehydrogenase, isovaleryl-CoA dehydrogenase, isocitrate dehydrogenase, electron 
transfer flavoprotein and alpha- and beta-enolase which all show reduced expression 
levels in our DIGE analysis of the dystrophic heart. This agrees with a previous study 
by Zhang and colleagues (2008) who reported a perturbed mitochondrial proteome, 
with reductions in citrate synthase and creatine kinase enzymes and lowered ATP 
affinity of the mitochondria, leading to cardiac dysfunction and abnormal energy 
handling.  Another recent study showed that a drastic cytosolic calcium concentration 
increase, as seen in dystrophic affected fibres, led to mitochondrial calcium overload, a 
collapse of the potential gradient and dysfunction leading to cell death (Jung et al., 
2008). Our confocal microscopy analysis of the dystrophic heart shows no significant 
changes in the mitochondrial mass between normal and dystrophin-deficient heart, as 
judged by labelling with the chloromethyl-X-rosamine MitoTracker dye, which is drawn 
inside the mitochondria by their negative potential (Pendergrass et al., 2004). 
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3.3.6 Other proteins 
A contrasting result revealed in our DIGE analysis was that individual protein spots 
representing electron-transferring flavoprotein showed both an increased and decrease 
expression level. Electron transfer flavoprotein ubiquinone oxidoreductase transports 
electrons derived from the fatty acid oxidation pathway into the matrix of the 
mitochondria to aid in the respiratory chain system (Swanson et al., 2008). The effect 
of different isoforms of this protein is hard to interpret, but dystrophin deficiency must 
affect distinct isoform species in differing ways, applying post –translational 
modifications to adapt to a stressed environment. Pyruvate dehydrogenase is a large 
enzyme complex involved in cellular respiration, and highly aerobic tissues are 
dependant on the conversion of pyruvate to acetyl-CoA (Koukourakis et al., 2005). In 
this study, we observed that a number of isoforms of pyruvate dehydrogenase had a 
decrease in protein expression between normal and MDX heart tissue. A reduction in 
this enzyme could have a detrimental impact on the overall bioenergetics of the MDX 
heart. Isoforms of cardiac prohibitin are present in inner mitochondrial membrane and 
are responsible for efficient assembly of mitochondrial respiratory chain enzymes, and 
provide scaffolding duties for the mitochondrial membranes (Koukourakis et al., 2005). 
Although a decrease was not confirmed by immunochemistry in overall prohibitin 
expression, distinct subspecies may be affected in muscular dystrophy. Enolase is the 
only enzyme in the glycolytic pathway appears to be down-regulated, indicating that 
mitochondrial metabolism and stability is more affected in dystrophic related 
cardiomyopathy than glycolysis.  Another of the energy supply pathways affected is 
oxidative metabolism. Fatty acids are bound to albumin to overcome their low solubility 
in the cytoplasm as they are transported across the mitochondrial membrane 
(Bassingthwaighte et al., 1989). A reduction, seen with the DIGE analysis, in both 
albumin and the cardiac isoform fatty acid binding protein would starve the cell of 
essential energy supplies, which may trigger loss of contractile strength in dystrophic 
myofibres. An outer mitochondrial ion channel identified as a porin isoform forms a 
voltage-dependent anion channel, VDAC1. The large complex of proteins form 
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membrane spanning channels that function to maintain ion homeostasis. A reduction in 
porin channels would indicate an abnormal ion handling leading to further disruption in 
the mitochondria.  
In contrast to a combined metabolomic and proteomic study of the MDX heart 
(Gulston et al., 2008) but in agreement with two comprehensive proteomic studies on 
MDX skeletal muscle (Doran et al., 2004; Doran et al., 2006b) we showed here a 
decrease in adenine nucleotide transport enzyme, the AK1 isoform of adenylate 
kinase. This finding was clearly confirmed using immunoblot analysis. Another 
nucleotide metabolism enzyme, creatine kinase also followed this disturbed 
concentration in the dystrophic heart tissue. These ATP transport pathways may be 
useful for the future development of a comprehensive biomarker signature of 
cardiomyopathy associated with muscular dystrophy. 
3.4 Conclusion 
Overall, our DIGE-based screening of the soluble proteome from dystrophic MDX 
hearts revealed a severely disturbed perturbed protein expression pattern due to the 
deficiency in dystrophin. A significant portion of this change was found in energy 
transport and metabolism proteins. As the stability of the mitochondria may be affected, 
indirectly by the loss of dystrophin, their affinity to bind phosphonucleosides is being 
influenced. The drastic increase in regulatory enzymes involved in homeostasis of 
intracellular ADP and ATP molecules may signal this loss in affinity of the 
mitochondria, as the dystrophin-deficient muscle responds to this stress of an increase 
in serum ATP. Furthermore, the drastic reduction in an antioxidative stress protein 
means that the myofibre is less able to counteract the increased disturbance due to the 
altered energy transfer and this may augment the stress and damage occurring in the 
dystrophic heart fibre. The phenotypic muscle weakness seen in dystrophic cardiac 
tissue may be due to loss of available energy to perform actions and of structural 
disorganization due in part to the decrease in concentration of the large myosin-related 
proteins. The observed changes in essential proteins involved in cardiac contraction, 
mitochondrial metabolism, the cellular stress response and nucleotide metabolism 
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might be useful for the future improvement of early cardiac diagnostic procedures, the 
identification of novel therapeutic targets to treat cardiomyopathic complications in 
Duchenne muscular dystrophy and the evaluation of novel treatment strategies to 
counteract the loss in cardiac dystrophin.  
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4 Proteomic profiling of naturally protected extraocular 
muscles from the dystrophin-deficient MDX mouse 
4.1 Introduction 
X-linked Duchenne muscular dystrophy is an extremely progressive neuromuscular 
disorder of childhood, however, not all types of muscle are affected similarly. While 
diaphragm is drastically weakened, the gastrocnemius is progressively affected and 
the laryngeal and extraocular muscles are usually spared. We carried out a 
comparative proteomic study of naturally protected extraocular muscle of the 
established MDX mouse model of X-linked muscular dystrophy.  
4.1.1 Duchenne muscular dystrophy and the extraocular muscle 
Dystrophinopathies are characterized by a primary deficiency in the Dp427 isoform of 
the membrane cytoskeletal protein dystrophin (Ahn and Kunkel, 1993). The loss in this 
large protein causes secondary effects leading to muscle damage and weakness due 
to sarcolemmal instability, alterations in ion homeostasis, metabolic pathways and 
cellular signalling and disturbance of the excitation-contraction coupling (Emery, 2002). 
As dystrophin anchors large membrane spanning glycoprotein complexes within the 
cell, membrane rupturing due to its deficiency leads to loss of membrane integrity. The 
reduced presence of the dystroglycan (DG) complex is believed to play a fundamental 
role in the degeneration of dystrophic muscles. However, not all subtypes of skeletal 
muscle are affected to the same extent in X-linked muscular dystrophy. The laryngeal 
and certain distal muscle fibres, as well as extraocular muscle (EOM), are protected 
from a severely degenerative phenotype in dystrophic organisms (Dowling et al., 2002; 
Dowling et al., 2003; Marques et al., 2007).  
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4.1.2 Properties of extraocular muscle 
Characterization of these naturally protected muscles may lead to the identification of 
constitutive properties or adaptive mechanisms that may cause the sparing of EOM in 
dystrophinopathies (Andrade et al., 2000). Although described as a skeletal muscle the 
histology, biochemical and physiological character of EOM is markedly different from 
other skeletal muscles. In limb muscle fibres, the speed of contraction is controlled 
principally by the type of myosin heavy chain (MHC) isoform expressed. An extraocular 
specific (MHC) isoform along with cardiac MHC and a developmental MHC are 
expressed in the fast twitch, fatigue resistant EOM. MHCEOM although abundantly 
expressed in EOM is not found in skeletal muscle. Usually fast-twitching muscles are 
not fatigue resistant. However, large bunches of mitochondria found in EOM may 
contribute to this muscle subtype physiology (Fischer et al., 2002; Stirn Kranjc et al., 
2009). Another physical difference between EOM and other skeletal muscles is the 
finding by Porter and colleagues (2003a) of the lack of an M-line in the contractile 
apparatus of EOM. The co-ordination action of six EOMs (see Figure 4-1) allows the 
eye to perform a variety of movements, with the rectus fibres located around the globe 
of the eye providing a rotation function and the oblique muscle providing a pulley 
system, to allow the eye to move about its vertical, horizontal and anteroposterior axis.  
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Figure 4-1 Diagrammatic representation of the extraocular muscles 
Shown is the location of the six fatigue-resistant extraocular muscles; Superior rectus, 
Inferior rectus, Lateral rectus and Medial rectus muscles allowing for rotational upward, 
downward, outward and inward movement respectively and Superior oblique and 
Inferior oblique muscles co-ordinating rolling movements. The accessory extraocular 
muscle Superior levator palpebrae lifts the eyelid 
http://www.arthurs-clipart.org/medical/senseorgans/page_01.htm 
4.1.3 Proteomics and extraocular muscle 
Proteomic profiling of Dp427-deficient leg, diaphragm and cardiac muscles has 
revealed drastic changes in the expression levels of adenylate kinase, heat shock 
proteins, calcium binding proteins and many proteins involved in the energy generating 
metabolic pathways and contractile muscle proteins (Dowling et al., 2004b; Doran et 
al., 2006b; Lewis et al., 2010b). Porter and colleagues (2003b) have shown that within 
the six different dystrophin-deficient EOM muscle types, all are absent in dystrophin but 
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that three fibre types have up-regulated dystrophin homologue, utrophin.  Contrary to 
skeletal muscle they demonstrate that there are no degeneration-regeneration cycles 
in the spared dystrophic EOM. In contrast to skeletal muscle fibre types, 
immunoblotting for ß-dystroglycan (ßDG) demonstrates the membrane complex to be 
preserved in naturally protected phenotypes of MDX myofibres (Dowling et al., 2004a).  
4.1.4 Experimental design 
Since Dp427-deficient fibres appear not to be affected in a major way, we have 
carried out a mass spectrometry (MS)-based proteomic comparison of normal versus 
MDX EOM fibres. The MDX mouse represents an established animal model of DMD, 
which exhibits severe muscle degeneration in the diaphragm, segmental necrosis in 
limb muscles and a mild phenotype in EOM (Bulfield et al., 1984). Here we have used 
fluorescence difference in-gel electrophoresis (DIGE), one of the most powerful tools 
available in biochemistry (Viswanathan et al., 2006), to study potential changes in 
protein expression levels in Dp427-deficient versus normal EOM preparations. This 
report describes analysis of DIGE labeled normal and dystrophic EOM MDX tissue of 
9-week old dystrophin-deficient versus age-matched normal extraocular muscle. Using 
a pH 4-7 range, out of 1,088 recognized protein spots we identified a moderate 
expression change in only 7 protein species. These proteins of interest were digested 
and identified via ESI LC-MS. An immunoblotting study revealed drastic up-regulation 
of dystrophin homologue protein and also an increased concentration of stress 
response proteins.  
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4.2 Results 
4.2.1 Comparative proteomic analysis of MDX versus normal extraocular 
muscle 
Since EOM tissues exhibit a uniquely mild phenotype in a dystrophic tissue, we 
performed a comparative proteomic analysis of normal versus MDX preparations of 
extraocular muscle. Optimized for the small size of murine extraocular tissue and 
following the recommendations of Karp and Lilley (2007) three biological replicates for 
each sample type was run using a two dye system. Each replicate contained a pool of 
two pairs of extraocular muscle. Figure 4-2 illustrates representative two-dimensional 
gels of Cy3-labelled normal and dystrophic EOM tissue and corresponding Cy5-
labelled pooled standards. Gel electrophoretically separated protein spots were 
analyzed with the help of a Typhoon Trio variable imager and Progenesis 2-D analysis 
software. Overall, 1,088 distinct muscle protein species were recognized in slab gels 
with an isoelectric focusing range of pH 4-7. We employed this pH-range in the first 
dimension step taking into account the high cost of DIGE materials, the limited sample 
size and from a previous study, showing that the majority of separated soluble crude 
muscle proteins are identified within this range (Lewis et al., 2010b). Seven spots 
showed a moderate differential expression pattern, with three proteins being increased 
and four proteins showing decreased expression. Electrospray ionization mass 
spectrometry analysis was carried out to identify the extraocular proteins with changes 
abundance in dystrophic tissue. 
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Figure 4-2 2-D DIGE analytical gel of normal versus MDX extraocular muscle in the pH 4-7 range 
Shown are the Cy3-labelled gels of total extract from normal (A) and dystrophic MDX 
(C) EOM tissue, as well as Cy5-labelled gels containing pooled standards (B,D). DIGE 
images are shown for the pH4-7 range. The pH-values of the second dimension are 
indicated on the top and the left of the panels, respectively. 
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4.2.2 DIGE analysis of dystrophin-deficient extraocular muscle 
A list of the extraocular proteins with significantly altered expression level in the 
dystrophic MDX tissue is shown in Table 4-1. The information on the seven DIGE 
identified protein spots from the   4-7 pH range contains protein name, fold change, 
matched peptides, number of matched peptides, percentage sequence coverage, the 
relative molecular mass, pI values, Mascot score and protein ID of individual proteins 
affected by deficiency in Dp427. An analytical master gel (Figure 4-3) shows the 
moderate changes that were found in muscle proteins marked and numbered 1 to 7 in 
the Cy5-labelled gel, so that it is possible to correlate MS-identified protein species, 
listed in Table 4-1, with distinct two-dimensional spots of altered density in MDX EOM 
preparations. MS analysis identified the increased proteins as the muscle-specific 
intermediate filament protein desmin (spot 1), apolipoprotein A-I binding protein (spot 
2) and perilipin-3 (spot 3) and the decreased proteins as cytosolic gelosin (spot 4), 
gephyrin (spot 5), transaldolase (spot 6) and acyl-CoA dehydrogenase (spot 7).  
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Table 4-1 List of the DIGE-identified proteins with a changed abundance in dystrophic MDX 
extraocular muscle 
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1 Desmin 2.1 2 4 53.5 5.21 51 gi|33563250| 
2 
Apolipoprotein A-I 
binding protein 
precursor 
1.8 5 30 31.3 7.59 65 gi|21553309| 
3 Perilipin-3 1.5 6 21 47.3 5.45 204 gi|13385312| 
4 Gelsolin, cytosolic -1.4 1 2 81.1 5.53 92 gi|90508| 
5 Gephyrin -1.7 6 11 82.0 5.45 139 gi|148670669| 
6 Transaldolase -1.8 12 33 37.5 6.57 147 gi|33859640| 
7 
Acyl-CoA 
dehydrogenase 
precursor 
-1.9 16 45 48.3 8.34 321 gi|31982520| 
 
* The Mascot score has a 95% confidence level if >20
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Figure 4-3 DIGE analysis of MDX extraocular tissue  
Shown is a Cy5-labelled master gel of crude tissue extracts from EOM tissue 
covering the pH 4-7 range. Protein spots with a moderately changed expression in 
MDX preparations are marked by circles and are numbered 1-7. See Table 4-1 for a 
detailed listing of these EOM-associated proteins with a changed abundance in the 
MDX mouse. The pH-values of the first dimension gel system and molecular mass 
standards (in kDa) of the second dimension are indicated on the top and on the left of 
the panels, respectively. 
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4.2.3 Immunoblot analysis of dystrophin-deficient extraocular muscle 
In order to further characterize the EOM phenotype, comparative immunoblotting was 
carried out. The immunoblot analysis shown in Figure 4-4 reveals a drastic down-
regulation of dystrophin and a drastic up-regulation of Up395, in Dp427-deficient EOM 
preparations. Immuno-decoration experiments clearly illustrate that the expression of 
the dystrophin-associated glycoprotein ß-DG is drastically reduced in severely 
degenerative MDX diaphragm, but is of comparable levels in MDX EOM tissue as 
shown in Figure 4-5. The same is true for CSQ where a previous study shows a 
reduction in MDX diaphragm preparation (Doran et al., 2006a), our study confirms this 
decrease in MDX diaphragm but shows a rescue in the expression of this calcium 
storage protein in MDX EOM tissue (Figure 4-6). This figure also shows the calcium 
pump SERCA1 not to be changed in any major way in MDX mice. An immunoblot of 
laminin and ATPß synthase mitochondrial isoform, unchanged in MDX tissue shows 
equal loading of the PAGE gels (Figure 4-7). An immunoblotting survey of key stress 
proteins demonstrated a drastic increase of essential Hsp elements in mildly dystrophic 
EOM preparations. The expression of the small stress proteins αßCrystallin, cvHsp 
and Hsp25 was elevated in Dp427-deficient EOM tissue (Figure 4-8). In contrast to 
decreased levels of Hsp90 in the dystrophic diaphragm, this large stress protein was 
shown to be increased in MDX EOM (Figure 4-9).  
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Figure 4-4 Immunoblotting analysis of MDX EOM tissue.  
Shown are the immunoblots using antibodies to dystrophin full-length isoform Dp427 
(A) and utrophin Up395 (B). The concentration of dystrophin was shown to be 
drastically down-regulated between normal lane 1 (A) and and dystrophic lane 2 (A) 
EOM preparation. Whereas the concentration of utrophin was shown to be drastically 
up-regulated between normal lane 1 (B) and dystrophic lane 2 (B) EOM preparation. 
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Figure 4-5 immunoblotting analysis of ßDG in MDX tissues 
Shown is the immunoblot using antibody specific ßDG in severely affected diaphragm 
muscle, showing a significant difference in the concentration of ßDG between normal 
diaphragm lane 1 (A) and dystrophic diaphragm lane 2 (A). Shown also is the 
immunoblot using ßDG antibody in mildly affected EOM muscle (B). The concentration 
of ßDG was found not to significantly different between normal lane 1 (B) and 
dystrophic lane 2 (B) EOM preparation. Graphical presentation of the statistical 
evaluation (C) carried out of the comparative blotting was statistically evaluated using 
an unpaired Student’s t-test (n=3;??p<0.01). 
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Figure 4-6 Immunoblot analysis of calcium-handling proteins in MDX tissue 
Shown are the immunoblots with graphical presentation of the statistical evaluation of 
immuno-decoration using antibodies to calcium handling calsequestrin CSQ (A,B) and 
SERCA1 skeletal isoform (D,E). The comparative blotting was statistically evaluated using 
an unpaired Student’s t-test (n=3). The concentration of calsequestrin (C) and SERCA1 (F) 
was found not to significantly different between normal and dystrophic EOM preparation. 
Lanes 1 and 2 represent normal and dystrophic muscle extracts from control and MDX 
mice, respectively. 
CSQ 
Normal           MDX 
c 
Normal           MDX 
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Figure 4-7 Immunoblot analysis of unchanged proteins 
Shown are representative blots of the equal loading protein laminin and the 
unchanged protein ATP synthase. Laminin was shown to be equally loaded in MDX 
diaphragm (A) and also in MDX EOM (B). ATPß synthase (D) was shown to be 
unchanged in MDX EOM. The comparative blotting was statistically evaluated using an 
unpaired Student’s t-test (n=3). The concentration of Laminin (C) and ATP synthase 
(E) was found not significantly changed in dystrophic tissue preparations. Lanes 1 and 
2 represent normal and dystrophic muscle extracts from control and MDX mice, 
respectively 
 91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-8 Immunoblot analysis of small heat shock proteins 
Shown are the representative immunoblots expanded views of immuno-decorated bands 
labeled with antibodies to αßCrystallin (A), cvHsp (C) and Hsp25 (E). The comparative blotting 
was statistically evaluated using an unpaired Student’s t-test (n=3;?p<0.05, ??p<0.01). The 
concentration of all small heat shock proteins were found to be significantly increased between 
normal and dystrophic EOM preparation. Lanes 1 and 2 represent normal and dystrophic muscle 
extracts from control and MDX mice, respectively 
Normal              MDX 
Normal              MDX 
Normal              MDX 
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Figure 4-9 Immunoblot analysis of large heat shock protein 90 
Shown are the representative immunoblots with expanded views of immuno-
decorated bands labeled with antibody to a large heat shock protein Hsp90. Dystrophic 
diaphragm preparation (A) and dystrophic EOM (B) show opposite fates. The 
comparative blotting was statistically evaluated using an unpaired Student’s t-test (n=3; 
?p<0.01). The concentration of Hsp90 was found to be significantly different in MDX 
EOM preparation (C). Lanes 1 and 2 represent normal and dystrophic muscle extracts 
from control and MDX mice, respectively 
Normal                   MDX 
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4.3 Discussion 
As compared to non-fluorescent protein dye approaches, the application of 
fluorescent CyDyes has decisively improved the dynamic range of protein coverage in 
comparative proteomic studies (Karp and Lilley, 2005; Viswanathan et al., 2006). We 
have therefore used the highly accurate quantitative DIGE technique for the analysis of 
the mildly affected EOM from the MDX model of DMD. In other subtypes of skeletal 
muscles, the deficiency in Dp427 causes downsteam alterations (Emery, 2002). 
Proteomic studies have clearly established a generally perturbed protein expression 
pattern in MDX diaphragm muscle (Doran et al., 2006b). It is crucial to employ an 
extremely sensitive biochemical method in order to be able to detect minor changes in 
a naturally protected phenotype of dystrophinopathy. Since the fluorescent DIGE 
technique enables multiple protein samples to be separated on the same two-
dimensional gel, potential artefacts due to gel-to-gel variations are greatly reduced 
(Viswanathan et al., 2006). Hence, DIGE analysis suggests itself as an ideal analytical 
tool to conduct a comparative investigation into the proteomic changes in MDX EOM 
versus normal EOM preparations. The proteomic findings presented here agree with 
the idea that EOM tissue is only marginally affected by the loss in Dp427. 
4.3.1 Moderate expression changes of DIGE EOM analysis 
A moderate change in abundance in seven EOM-associated proteins, as shown here 
by DIGE analysis, is in stark contrast to major alterations in 35 diaphragm proteins, as 
previously shown by MS-based studies (Doran et al., 2006b). The approximately 2-fold 
increase in muscle-specific desmin is an interesting finding, since it supports the 
hypothesis that the loss in Dp427 is partially compensated in EOM tissue by 
strengthening the intermediate filament network. High levels of desmin might stabilise 
the small diameter EOM fibres and thereby protect them from extensive contraction-
induced injury in the absence of Dp427. The higher concentration of apolipoprotein A-I 
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binding and perilipin-3 suggests an increased utilisation of lipid metabolism. 
Apolipoprotein A-I binding protein interacts with apolipoprotein A-I, a crucial constituent 
of high-density lipoprotein, and is involved in cholesterol efflux mechanisms. Perilipin-3 
is a lipid droplet-associated protein that functions as a protective coating against 
lipases. An increased level of both proteins might support the altered metabolic needs 
of Dp427-deficient EOM fibres. The decreased levels of gelosin, gephyrin, 
transaldolase and acyl-CoA dehydrogenase have probably an effect on structural and 
metabolic mechanisms. Gelosin is an actin-binding element that regulates actin 
filament assembly and disassembly and gephyrin is a tubulin-binding protein involved 
in clustering of glycinergic and GABAergic receptors. Hence, a reduced density in 
these two binding proteins might affect actin-based cytoskeletal stability and trigger a 
certain degree of post-synaptic disturbances in Dp427-deficient EOM fibres. Lower 
levels of transaldolase and acyl-CoA dehydrogenase indicate moderate changes in 
metabolite utliisation. Transaldolase represents a non-oxidative enzyme of the pentose 
phosphate pathway and links this metabolic system to glycolysis. Acyl-CoA 
dehydrogenase is a crucial mitochondrial enzyme involved in fatty acid metabolism. 
Decreased densities of these two enzymes might therefore impair key metabolic 
processes, including the glycolytic pathway and fatty acid ß-oxidation.  
4.3.2 Immunoblotting survey of MDX EOM tissue 
In contrast to the above discussed moderate changes in structural and metabolic 
elements as determined by DIGE analysis, immunoblotting demonstrated on one hand 
the rescue of key muscle proteins in MDX EOM and on the other hand a drastic up-
regulation of proteins belonging to the Hsp family of molecular chaperones. These 
alterations were probably not detected by proteomics due to the low abundance of 
these proteins in conventional two-dimensional gels. Interestingly, the drastic increase 
in Up395 in Dp427-deficient EOM tissue is associated with comparable levels of the 
crucial dystrophin-associated glycoprotein ß-DG and the luminal Ca2+-binding protein 
CSQ. Both proteins are greatly reduced in the dystrophic diaphragm and are believed 
to be major pathophysiological factors in DMD (Pertille et al., 2010). The secondary 
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loss in ß-DG causes the disintegration of sarcolemmal stability and subsequent Ca2+-
dependent necrotic changes in muscular dystrophy. Low levels of CSQ seem to 
exacerbate abnormal cytosolic Ca2+-handling by impaired luminal Ca2+-buffering in the 
dystrophic sarcoplasmic reticulum. These pathological alterations appear not to be 
present in MDX EOM tissue, which agrees with the previously reported resistance of 
dystrophic EOM fibres to Ca2+-induced muscle degeneration (Khurana et al., 1995).  
4.3.3 Perturbed stress response in MDX EOM tissue 
The drastic increase in molecular chaperone protein suggests that MDX EOM is 
capable of sustained cellular stress responses, involving both low- and high-molecular-
mass Hsp elements. Since small Hsps are especially associated with the repair of the 
cytoskeletal network in skeletal muscle (Nicholl and Quinlan, 1994), the up-regulation 
of Hsp25, αßC and cvHsp might be linked to the DIGE-determined increase in desmin. 
In general, stress proteins facilitate the stabilisation or elimination of misfolded proteins 
or peptide clusters in order to prevent the deleterious accumulation of non-functional 
protein aggregates (Boluyt et al., 2006). Chaperone activity probably plays an 
important role in the rescue mechanisms that are intrinsic to EOM fibres.  
4.4 Conclusion 
In conclusion, this proteomic and biochemical study clearly showed that the mild 
phenotype of MDX EOM is associated with (i) only a limited number of metabolic and 
structural systems being perturbed, (ii) a drastic increase in Up395 and a concomitant 
rescue of sarcolemmal ß-DG, (iii) comparable levels of key Ca2+-handling proteins, and 
(iv) a drastic increase in molecular chaperones. Thus, the up-regulation of Hsps and 
the rescue of the luminal Ca2+-uptake apparatus in MDX EOM tissue, as well as the 
extra-junctional expression of Up395, are probably crucial for preventing severe 
muscular dystrophy. This makes these proteins potential pharmacological targets for 
the development of future therapies to treat DMD. In addition, the small diameter and 
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limited load bearing of EOM fibres might also be critical factors that render this subtype 
of skeletal muscle extremely resistant to cellular degeneration. 
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5 Mass spectrometric identification of dystrophin isoform 
Dp427 by ‘on-membrane’ digestion of sarcolemma from 
skeletal muscle 
5.1 Introduction 
Although the membrane cytoskeletal protein dystrophin of 427kDa and its tightly 
associated glycoprotein complex are drastically affected in muscular dystrophy, recent 
large-scale proteomic investigations did not identify full-length dystrophin in muscle 
preparations and were unable to be determine its molecular fate in dystrophinopathy 
(Ge et al., 2003; Doran et al., 2006a; Doran et al., 2006b). Since conventional two-
dimensional gel electrophoresis under-represents many low-abundance and 
membrane-associated protein species and in-gel trypsination is often hampered by an 
inefficient digestion of certain target proteins (Luque-Garcia et al., 2006), we have here 
applied direct on-membrane digestion of one-dimensional blots of the sarcolemma-
enriched fraction and the isolated dystrophin-glycoprotein complex. This method 
described by Aebersold (1987) succeeded in the mass spectrometric identification of 
dystrophin isoform Dp427 and associated glycoproteins, as well as sarcolemmal 
dysferlin. In addition, protein bands representing established signature molecules of 
cross-contaminating membrane systems, such as the voltage-gated dihydropyridine 
receptor of transverse tubules, the ryanodine receptor Ca2+-release channel of triad 
junctions and the Ca2+-ATPase of the sarcoplasmic reticulum, were identified by mass 
spectrometry. Thus, proteomic approaches using on-membrane digestion might be 
suitable for future studies of low-abundance proteins, integral proteins, peripheral 
membrane proteins and high-molecular-mass proteins. On-membrane digestion has 
the potential to develop into the method of choice for studying these classes of 
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proteins, which presence is otherwise missed by conventional gel electrophoresis-
based proteomics . 
5.1.1 The sarcolemmal and associated proteins 
The sarcolemma provides a crucial structural attachment site for the basement 
membrane at the outside of the muscle cell and for the membrane cytoskeleton on the 
inside of contractile fibres, which strengthens the muscle periphery during contraction-
relaxation cycles. The membrane cytoskeletal protein dystrophin and its tightly 
associated glycoprotein complex play a key role in the stabilisation of the fibre surface 
by providing a linkage between the extracellular matrix component laminin and the 
cortical actin cytoskeleton (Ervasti and Campbell, 1993). Full-length dystrophin has an 
molecular mass of apparent 427kDa and exhibits a complex domain structure. The 
membrane cytoskeletal element consists of an N-terminal actin-binding domain, a 
central spectrin-like rod domain with proline-rich hinge regions, a cysteine-rich domain 
and a C-terminal region containing membrane-binding sites (Koenig and Kunkel, 
1990). Although biochemical and cell biological studies have clearly shown that the 
primary genetic deficiency results in the drastic reduction of the dystrophin-associated 
glycoprotein complex in linked muscular dystrophy (Ohlendieck et al., 1993), recent 
large-scale proteomic studies have surprisingly not identified dystrophin isoform Dp427 
in gel electrophoretically separated muscle preparations (Ge et al., 2003; Doran et al., 
2004; Doran et al., 2006a; Doran et al., 2006b; Lewis et al., 2010b). These mass 
spectrometric gel-based proteomic studies have revealed many changes in many novel 
biomarkers of muscular dystrophy such as the adenylate kinase enzyme (Ge et al., 
2003), the sarcoplasmic reticulum Ca2+-binding protein calsequestrin (Lohan and 
Ohlendieck, 2004), the cytosolic Ca2+-binding protein regucalcin (Doran et al., 2006a) 
and the small stress response protein cardiovascular heat shock protein (cvHsp) 
(Doran et al., 2006b), but appears not to be suitable for detecting alterations in 
elements of the dystrophin-glycoprotein complex, due to the large size of key proteins, 
integral transmembrane domains and tightly bound complexes.  
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5.1.2 Advantages of on-membrane digestion 
Conventional two-dimensional gel electrophoresis under-represents many low-
abundance and membrane-associated protein species when analysing complex protein 
mixtures (Wittmann-Liebold et al., 2006; Rabilloud et al., 2009). In addition, an 
inefficient digestion of certain target proteins often hampers in-gel trypsination 
procedures. To address these technical shortcomings in the proteomic identification 
and biochemical analysis of dystrophin, we have investigated here whether direct on-
membrane digestion of one-dimensional blots containing the sarcolemma-enriched 
fraction or the isolated dystrophin-glycoprotein complex from skeletal muscle can 
overcome these methodological problems. In general, proteins adsorbed onto 
nitrocellulose sheets are more accessible to proteases increasing the digestion 
efficiency (Luque-Garcia et al., 2006). On-membrane trypsination methods have been 
applied in various biochemical studies (Towbin et al., 1979; Aebersold et al., 1987; 
Luque-Garcia et al., 2008). The advantages of on-membrane methodology are better 
protein sequence coverage and a shorter digestion time as compared to in-gel 
techniques. This reduces complications due to trypsin autolysis and makes this method 
especially useful for the mass spectrometric identification of low-abundance and large 
membrane associated proteins. This technique might also be useful for the routine 
analysis of the dystrophin-glycoprotein complex in normal and pathological muscle 
samples. Importantly, it may also be suitable for studying the fate of high-molecular-
weight muscle proteins that would otherwise not be properly recognised using 
conventional two-dimensional gel electrophoretic approaches. 
5.2 Results 
5.2.1  Subcellular fractionation 
In order to separate the high-molecular-mass band of the 427kDa dystrophin protein 
from other large muscle proteins and be able to visualise and identify a distinct Dp427-
containing band, a combination of subcellular fractionation and gradient gel 
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electrophoresis was carried out on this complex protein mixture. This work was carried 
out prior to the beginning of this on-membrane study, by the supervisor of this project, 
Professor Kay Ohlendieck. I took no part in the subcellular fractionation portion of this 
study but I will provide a brief outline to clarify the workflow. The flowchart Figure 5-1 
outlines the subcellular fractionation procedure to separate the sarcolemma-enriched 
fraction from the remaining cell contents. The nuclei, contractile apparatus, the cellular 
debris, mitochondria, cytosolic proteins were separated out to leave microsomes. 
Membrane fractions containing surface membranes, triad junctions, transverse tubules 
and the sarcoplasmic reticulum were isolated by density gradient centrifugation as 
described by Ohlendieck and colleagues (1991). The dystrophin-glycoprotein complex 
was then isolated from the microsome fraction by a chromatography and centrifugation 
method described by Ervasti and colleagues (1990). In skeletal muscle, the 
plasmalemma membrane, in contrast to the sarcoplasmic reticulum and associated 
triad structures, represents a much less abundant membrane system (Ohlendieck et 
al., 1991). Therefore, it is likely that that various abundant membrane species cross-
contaminate sarcolemmal preparations during differential and density gradient 
centrifugation steps. 
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Figure 5-1 Enrichment of sarcolemmal proteins 
Outline of the preparation of the sarcolemma-enriched fraction from skeletal muscle 
homogenates using differential centrifugation, sucrose density gradient centrifugation 
and lectin agglutination (WGA, wheat germ agglutinin; NAG, N-acetylglucosamine). A 
series of low speed centrifugation steps removed the nuclei, contractile apparatus, cell 
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debris, mitochondria and cytosolic elements with a final centrifugation step leaving 
supernatant containing only microsomes. The dystrophin-glycoprotein complex was 
isolated from microsomes by addition of the detergent, digitonin, to solubilise the 
membranes and separated by charge and size using liquid chromatography and 
density gradient centrifugation, respectively. The purified sarcolemma was isolated by 
performing a density gradient centrifugation step on a batch of microsomes. Different 
membrane cell elements separated out according to size and the surface membrane 
portion of the supernatant containing intact vesicles were separated out using wheat 
germ agglutination which bind to the glycoproteins displayed on the exterior of the 
sarcolemmal membranes. 
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5.2.2 SDS-PAGE fractionation 
Following subcellular fractionation, a mass spectrometry-based study was carried 
out. The flowchart shown in Figure 5-2 outlines the proteomic analysis from 
polyacrylamide gel separation to protein identification via mass spectrometry. The 
major membranes of skeletal muscle tissues are diagrammatically shown in Figure 5-3. 
For comparative purposes, the subcellular localisation of marker proteins that were 
identified by mass spectrometry in this study is illustrated in the diagram. The 
Coomassie stained gel of Figure 5-4A illustrates the considerable difference in the 
protein band pattern of the sarcoplasmic reticulum, triad junctions, transverse tubules 
and sarcolemma. Following electroblotting, the successful transfer of proteins was 
visualised by staining of nitrocellulose replicas with the reversible stain MemCode 
(Figure 5-4B).  
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Figure 5-2 Analytical strategy to study the dystrophin-glycoprotein complex 
Shown is the overview of the analytical strategy to study the isolated sarcolemma 
protein complexes by mass spectrometry-based proteomics. Sarcolemmal proteins 
were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Transferred to nitrocellulose membrane and then individual bands digested by 
on-membrane trypsination. Muscle proteins were identified by electrospray mass 
spectrometry (ESI-MS). 
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Figure 5-3 Major membranes of skeletal muscle 
Shown is the diagrammatic presentation of major muscle membrane systems in 
skeletal muscle fibres and the subcellular localisation of established marker proteins. 
Membrane systems can be divided into the sarcolemma (SL), transverse tubules (TT), 
triad junctions (TR), the sarcoplasmic reticulum (SR) and mitochondria (MT), whereby 
established markers of these fractions are represented by dysferlin, the dihydropyridine 
receptor (DHPR) the ryanodine receptor (RyR), Ca2+-ATPase isoform SERCA and the 
F1-ATPase, respectively. In addition, soluble elements of the extracellular space (ES), 
such as albumin, or abundant glycolytic enzymes of the cytosol (CYT), such as 
aldolase, may become entrapped in vesicular membrane preparations derived from 
muscle homogenates.  
 
 106 
 
Figure 5-4 Protein band pattern of fractionated muscle membranes 
Shown is the Coomassie-stained gel of the sarcoplasmic reticulum, triads, transverse 
tubules and sarcolemma (A). Also shown is the nitrocellulose replica of the 
sarcoplasmic reticulum, triads, transverse tubules and sarcolemma stained with the 
reversible dye MemCode (B). Molecular mass standards (in kDa) are shown on the left 
of the panels. 
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5.2.3 Sarcolemma-enriched fraction 
As shown in the representative nitrocellulose sheet of Figure 5-5, for the mass 
spectrometric analysis of the sarcolemma-enriched fraction, gel electrophoresis of 
muscle proteins was performed without combs so that several centimetre-long 
horizontal strips of individual proteins bands could be separated. MemCode-stained 
nitrocellulose sheets were cut into 41 individual bands and then digested with trypsin. 
The mass spectrometric analysis identified 16 individual muscle proteins with a high 
Mascot score, as listed in Table 5-1. Protein bands 1 to 16 contained several 
established marker proteins of subcellular fractions from the skeletal muscle. Bands 
1,3,4,5,6,11 and 16 represent the ryanodine receptor Ca2+-release channel isoform 
RyR1 of the triad junction, dysferlin of the sarcolemma, myosin heavy chain MHC1 of 
the contractile apparatus, the voltage-sensing α1S-subunit of the dihydropyridine 
receptor L-type Ca2+-channel of the transverse tubules, the fast SERCA1 isoform of the 
sarcoplasmic reticulum Ca2+-ATPase, the mitochondrial F1-ATPase and the abundant 
glycolytic enzyme aldolase of the cytosol, respectively. Thus, besides an enrichment of 
the sarcolemmal marker dysferlin, the plasma membrane preparation analysed in the 
report contained contaminating or associated structures from the actomyosin 
apparatus and most major membrane systems present in contractile fibres. Other 
proteins present in this subcellular fraction were phosphofructokinase, albumin, 
calsequestrin, TRIM72 protein and flotilin (Table 5-1). Several proteins ould only be 
identified by 1 matched peptide and are therefore not listed in the Table 5-1. This 
included succinate dehydrogenase (2% coverage; 73.670 kDa; pI 7.06; Mascot score; 
75; gi│347134│), the α-subunit of sarcoglycan (3% coverage; 42.984 kDa; pI 5.76; 
Mascot score; 57; gi│126722611│), muscle creatine kinase (3% coverage; 43.247 
kDa; pI 6.63; Mascot score: 56; gi│180576│) and the α-chain of G-protein (4% 
coverage; 43.41.100 kDa; pI 5.36; Mascot score: 68; gi│309255│). 
Most importantly, as shown in Figure 5-5, the mass spectrometric analysis of the 
sarcolemma-enriched fraction by ‘on-membrane’ digestion identified the low-
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abundance membrane cytoskeletal protein dystrophin (band 2), as well as the tightly 
dystrophin-associated protein α-syntrophin (band 10). Previous mass spectrometry-
based proteomic profiling studies of total soluble skeletal muscle extracts have failed to 
detect dystrophin or its associated membrane proteins (Ge et al., 2003; Doran et al., 
2006b; Lewis et al., 2010b).  
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Figure 5-5 Identification of full-length dystrophin isoform Dp427 by on-membrane digestion ofhe 
sarcolemmal-enriched fraction from rabbit skeletal muscle.  
Shown is a representative MemCode-stained nitrocellulose replica of the 
electrophoretically separated sarcolemmal-enriched fraction, using a gel system 
without a comb for the generation of several centimeter long horizontal bands for on-
membrane digestion. Protein bands that were unequivocally identified by mass 
spectrometry are numbered 1 to 16 (Table 5-1), including elements of the dystrophin-
glycoprotein complex, such as dystrophin isoform Dp427 (band 2) and α-syntrophin 
(band 10). On the left side of the panel are marked established marker proteins of the 
various subcellular fractions of muscle, as described in Figure 5-3 
 110 
Table 5-1 Mass spectrometric identification of electrophoretically separated protein bands from 
the purified sarcolemma 
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1 
Ryanodine 
receptor, RyR1 
isoform, skeletal 
muscle 
3 1 570.381 5.61 176 gi|156119408| 
2 
Full-length 
dystrophin, 
Dp427 isoform, 
skeletal muscle 
4 1 427.067 5.63 224 gi|5032283| 
3 Dysferlin 4 2 241.329 5.42 245 gi|156523092| 
4 
Myosin heavy 
chain MHC1, 
skeletal muscle 
3 2 224.063 5.62 77 gi|109113269| 
5 
Dihydropyridine 
receptor, subunit 
α-1S, skeletal 
muscle 
4 2 214.002 6.16 162 gi|156119412| 
6 
Calcium- 
transporting 
ATPase, fast 
SERCA1 isoform, 
skeletal muscle 
4 4 111.756 5.14 219 gi|147903853| 
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7 
Phosphofructo-
kinase, skeletal 
muscle 
2 3 86.005 8.49 154 gi|125128| 
8 Albumin 3 6 70.861 5.85 107 gi|126723746| 
9 
Calsequestrin, 
isoform CSQ-1, 
skeletal muscle 
2 7 45.762 3.99 152 gi|149755961| 
10 
Syntrophin, alpha 
1 subunit, skeletal 
muscle 
2 4 54.187 6.06 104 gi|1438772| 
11 
ATP synthase, 
mitochondrial F1 
complex, beta 
subunit isoform 2 
3 8 56.410 5.2 195 gi|114644226| 
12 
Tripartite motif-
containing 
TRIM72 protein 
2 8 53.601 5.92 137 gi|126723064| 
13 Flotillin 2 6 47.769 6.71 79 gi|6679809| 
14 Enolase 2 2 47.381 7.63 58 gi|126723437| 
15 
Muscle creatine 
kinase 
4 11 43.433 6.63 186 gi|6729828| 
16 Aldolase 3 11 39.586 8.2 164 gi|6730618| 
* The Mascot score has a 95% confidence level if >20 
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5.2.4 Dystrophin-glycoprotein complex fraction 
Shown in Figure 5-6 is the mass spectrometric analysis of the purified dystrophin-
glycoprotein complex and Table 5-2 lists the details of the mass spectrometric 
identification of dystrophin (band 1), α-sarcoglycan (band 2) and γ-sarcoglycan (band 
3). The dystrophin-associated protein dystrobrevin could only be identified by 1 
matched peptide (2% coverage; 78.425 kDa; pI 6.34; Mascot score: 70; gi│1246783│) 
and is therefore not listed in Table 5-2. Representative results from LC-MS analysis 
and mass spectra of dystrophin from sarcolemmal preparations and the isolated 
dystrophin-glycoprotein complex are shown in Figure 5-7. 
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Figure 5-6 Identification of dystrophin by on-membrane digestion of the purified dystrophin-
glycoprotein complex from rabbit skeletal muscle. 
Shown is a representative MemCode-stained nitrocellulose replica of the 
electrophoretically separated dystrophin-glycoprotein complex, using a gel system 
without a comb for the generation of several centimetre long horizontal bands for on-
membrane digestion. Protein bands that were unequivocally identified by mass 
spectrometry are numbered 1 to 3 (Table 5-2), including dystrophin isoform Dp427 
(band 1), α-sarcoglycan (band 2) and γ-sarcoglycan (band 3). 
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Table 5-2 Mass spectrometric identification of electrophoretically separated protein bands from 
purified dystrophin-glycoprotein complex 
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2 14 32.359 5.12 90 gi|126723675| 
* The Mascot score has a 95% confidence level if >20 
 
 
 115 
 
Figure 5-7 Identification of full-length dystrophin isoform Dp427. 
Shown is the LC-MS analysis of the dystrophin band isolated from the sarcolemma-
enriched membrane fraction (A) or the purified dystrophin-glycoprotein complex (C) 
from rabbit skeletal muscle. Mass spectra of dystrophin are presented in panels (B) 
and (D). 
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5.3 Discussion 
Besides defining the physical integrity within contractile tissues by separating the 
fibre interior from the extracellular environment, the highly complex surface membrane 
system of skeletal muscle fibres plays a central physiological role in the neuromuscular 
transmission process, the propagation of action potentials, the maintenance on 
homeostasis, the regulation of excitation-contraction coupling, the control of metabolic 
fluxes and the provision of cellular signalling cascades for the swift physiological 
adaptation to changed functional demands. The biomedical fact that primary genetic 
abnormalities in proteins located on the surface membrane system are responsible for 
various neuromuscular pathologies emphasizes the importance for a detailed 
biochemical understanding of the composition and structure of the plasma membrane 
from skeletal muscle tissues. Individual sarcolemmal proteins have been studied for 
many years using conventional biomedical approaches, but its global protein 
composition is poorly understood. One possible way forward to catalogue the entire 
membrane protein complement of the fibre periphery is mass spectrometry-based 
proteomics.  
5.3.1 Modified proteomics study 
Proteomics had a major impact on the modern biosciences (de Hoog and Mann, 
2004) and decisively enhanced the field of basic and applied myology (Isfort, 2002). 
Proteomic profiling of muscle development, fibre differentiation and muscle 
transformation has identified a large cohort of new potential markers of muscle 
biochemistry and their role in physiological adaptations to changed functional demands 
(Ohlendieck, 2010). Mass spectrometry was also instrumental in the global analysis of 
common neuromuscular disease mechanisms. The proteomic analysis of muscular 
disorders has identified novel signature molecules involved in the molecular 
pathogenesis of muscular dystrophy and age-related muscle weakness (Doran et al., 
2006b; O'Connell et al., 2007; Lewis et al., 2010b). However, the majority of these 
studies have focused on the analysis of total extracts of the accessible skeletal muscle 
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proteome. Since the routine gel electrophoretic separation of crude protein extracts 
greatly under-estimates the presence of integral proteins, low-abundance elements, 
high-molecular-mass proteins and components with extremely acidic or basic pI-
values, previous analysis have been restricted to relatively soluble protein species. 
This is probably the main reason why proteomic studies of skeletal muscle tissues 
identify mostly abundant and soluble proteins, such as heat shock proteins, glycolytic 
enzymes and contractile proteins (Doran et al., 2006a; Doran et al., 2006b; Doran et 
al., 2008; Lewis et al., 2010b). However, the results shown here suggest that a 
modified subproteomic approach can be employed to also study membrane-associated 
and high-molecular-mass muscle proteins. 
5.3.2 ‘On-membrane’ digestion 
The successful identification of dystrophin isoform Dp427, as described in this report, 
demonstrates that one-dimensional gel electrophoresis, in combination with on-
membrane digestion, can overcome some of the technical problems of conventional 
two-dimensional gel electrophoretic techniques. Thus, in order to include the analysis 
of membrane-associated proteins in mass spectrometric studies, it is recommended to 
combine two-dimensional gel electrophoretic analysis of crude muscle extracts with on-
membrane digestion approaches and to enrich for low-abundance proteins by 
preceding on-membrane digestion with a subcellular fractionation step.  
5.4 Conclusion 
A more inclusive biochemical approach might be especially useful for the 
comparative proteomic screening of neuromuscular disorders where integral 
membrane proteins are often affected by complex down-stream abnormalities in 
muscle metabolism, signal transduction and ion homeostasis.  
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6 General Discussion 
Progressive X-linked muscular dystrophy represents the most commonly inherited 
neuromuscular disorder in humans. Although the disintegration of the dystrophin-
associated glycoprotein complex triggers the initial pathogenesis of Duchenne 
muscular dystrophy, secondary alterations in energy production, cellular signalling, 
cytoskeletal disorganisation and changes in ion homeostasis are probably critical 
factors that cause end-stage fibre degeneration (Carlson and Makiejus, 1990; Williams 
and Bloch, 1999). The application of mass spectrometry-based proteomics is routinely 
used to catalogue muscle biomarkers and has recently been applied to MDX animal 
model of muscular dystrophy and the biochemical evaluation of experimental exon 
skipping, as a possible suitable treatment for DMD (Doran et al., 2009). 
 
The overall objectives of this study was to study MDX in severely affected cardiac 
muscle, to investigate the naturally protective phenotype of extraocular MDX tissue and 
to modify the current mass spectrometry-based proteomic workflow to include analysis 
of the dystrophin-glycoprotein complex and associated integral proteins.  
 
Recent proteomic studies have demonstrated that mass spectrometry-based 
technologies can be used for studying a representative proportion of muscle proteins 
involved in contraction, regulation, metabolism, structure and cellular stress response 
(Doran et al., 2008; O'Connell et al., 2008; Lewis et al., 2010a). Proteomic profiling of 
muscle aims to quantitatively analyse the protein expression pattern of contractile 
fibres (Isfort, 2002) and then identifies the proteins of interest by high-throughput mass 
spectrometry. Mass spectrometry combined with fluorescence labelling methods can 
detect several thousand-muscle proteins in high-resolution 2D gel electrophoresis (2D-
GE) (Doran et al., 2006a). However, there are limitations to this method with respect to 
studying the entire cellular proteome (Rabilloud et al., 2009). High molecular mass 
proteins, membrane proteins and low-abundance proteins can be difficult to detect in 
polyacrylamide gels due to pore size, hydrophobic nature and dynamic range 
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respectively. Removal of the gel step has been attempted in order to gain a wider 
insight into the protein complement. Lu and colleagues (2008) demonstrated a 
complementary gel-free approach with it own limitations, although being able to 
substantiate “one-hit wonders”, the storage of massive amounts of MS-data and 
access to high tech MS equipment may be inaccessible to many laboratories. 
Separation via liquid chromatography prior to MS-protein identification too has it 
limitations as complex samples may have at least nine orders of magnitude of a 
concentration range (Pieper et al., 2003) making low-abundance proteins difficult to 
detect. We attempted in this study to optimise the MS-based proteomic workflow by 
carrying out a gel-based study with two pH ranges to achieve further separation 
(Chapter 3) prior to MS identification. Furthermore, we modified the pore size of the 
polyacrylamide gel and ran sub-fractionated samples to show the inclusion of high-
molecular mass integral proteins (Chapter 5).  
The loss of dystrophin, its associated proteins and individual sarcolemmal proteins 
have shown to be responsible for many neuromuscular disorders but due to the 
limitations of 2D-GE full-length dystrophin has not been identified in recent MS-
proteomic studies with many other novel biomarkers highlighted as changed in 
concentration. These markers are then secondary down-stream effects of the disease 
on muscle (Emery, 2002). Incorporating the on-membrane technique used in Chapter 5 
made possible the mass spectrometric identification of the high-molecular mass protein 
dystrophin and many of its associated proteins. Low-abundance protein changes in 
dystrophic tissue usually under-represented in 2D-GE studies were subsequently 
identified by specific antibody detection (Chapter 4). 
 
By studying two tissue types, one naturally protected against most neuromuscular 
dystrophies, we observed differences in the type of protein being expressed between a 
severely dystrophic phenotype and the naturally protected one. Figure 6-1 shows the 
flowchart of comparative proteomic analysis between these two tissue types. We found 
drastic changes in the expression of over 17 proteins plus an additional 55 moderate 
changes in cardiac tissue whereas we identified only seven moderate EOM changes in 
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a DIGE study. This relates directly to the severity of the disease. The majority of 
cardiac alterations were cytoskeletal proteins. It is interesting that an increase in 
intermediate filament proteins that provide membrane stability in the myofibre were 
drastically altered in cardiac tissue while only moderately increased in EOM. This 
suggests that EOM may be naturally protected by its physical property of small 
diameter fibres (Chapter 4). As seen in Chapter 3 though, a concomitant decrease in 
abundance in cardiac intermediate filament proteins displays the complexity of studying 
crude tissue and exhibiting the muscles ability to adapt to its changing surroundings. 
Additionally, it was observed that isoforms of the same protein display differential 
expression patterns, again displaying the complexity of the disease. These features 
demonstrate the benefits of 2D-GE in its ability to display crude soluble protein 
complement of muscle fibres. ATP production was badly affected in cardiac tissue 
whereas we saw only moderate changes in ATP production in the milder phenotype of 
the extraocular muscle. Both muscle types saw an increase in the stress response due 
to the lack of dystrophin, but a decrease in some small heat shock proteins and a 
similar change in larger stress proteins may contribute to the extra damage within the 
contracting myofibre as seen in the severely dystrophic cardiac tissue. While a drastic 
increased expression level of stress response proteins both large and small in EOM 
may protect the dystrophic tissue, explaining its milder phenotype. An alteration in the 
concentration of various cardiac cytoskeletal proteins is a likely cause of problems 
observed in the excitation-contraction coupling.  
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Figure 6-1. Flowchart of the comparative proteomic analysis of dystrophic cardiac tissue versus 
naturally protected extraocular muscle.  
The proteomic profiling of extraocular muscle (EOM) from dystrophin-deficient 
organisms should reveal protective mechanisms that prevent severe muscle 
degeneration in this subtype of skeletal muscle. In contrast to the lack of full-length 
dystrophin (Dp427), EOM exhibit an extra-junctional expression of a dystrophin 
homologue named utrophin (Up395). In healthy fibres, Up395 is restricted to the 
neuromuscular junction (NMJ). The supramolecular dystrophin-glycoprotein (DGC) of 
the sarcolemmal (SL) links the actin membrane cytoskeleton (AMC) to the extracellular 
matrix (ECM). Reduced levels of the dystrophin-associated glycoprotein complex 
(DAGC) trigger severe cellular abnormalities and are characteristic for the dystrophic 
phenotype 
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Sarcolemma disruption is high in cardiomyofibres (Lohan and Ohlendieck, 2004). The 
loss of dystrophin, which anchors the extracellular component laminin through to the 
actin cytoskeleton leads to a drastic reduction in the dystrophin-glycoprotein complex. 
One of these glycoproteins, ßDG is rescued in EOM (Chapter 4). The rescue of this 
sarcolemmal protein reduces the contraction-induced micro-rupturing normally seen in 
dystrophic tissue. Whereas cardiac fibres are replaced by connective tissue and 
become weakened, the EOM appear naturally protected. Interestingly, Porter and 
colleagues (2003b) studied the individual fibre types of the eye and found that three of 
the six dystrophic fibres did not show an expression of the dystrophin homologue, 
utrophin. These fibres also display a reduction in sarcolemma proteins but do not 
display the calcium-related muscle fibre degeneration. Our immunoblotting results 
showing comparable levels of calcium handling proteins agrees with this previously 
reported resistance of dystrophic EOM fibres to calcium-induced damage, suggesting 
no sarcolemma disruption in dystrophic EOM tissues (Chapter 4). 
 
From our studies we find that the EOM is under less stress than cardiac tissue. This 
is evident from the stress response possible due to the rescue of sarcolemma proteins 
and normal calcium handling abilities in EOM. The smaller diameter of the fibres may 
be more suitable to the replacement of utrophin and provide mechanical stability to the 
membrane. Although the eye muscle require vast ranges of movement they have a 
limited load bearing function, these may be critical factors that render this subtype of 
skeletal muscle resistant to fibre degeneration. A future MS-based proteomic study into 
the individual muscle subtypes within the eye may establish a novel mechanism to 
explain the spared dystrophic phenotype. 
 
Since the discovery of dystrophin and its involvement in Duchenne muscular 
dystrophy, several experimental treatment strategies have emerged. These include 
gene replacement in utero, myoblast transfer treatment and stem cell therapy. Exon 
skipping therapy, which produces a truncated dystrophin molecule similar to the 
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dystrophin isoform of the milder Becker muscular dystrophy, suggests itself as a novel 
therapeutic approach. A comparative proteomic approach was applied to evaluate 
exon skipping and a restoration of key muscle proteins was seen after the dystrophic 
diaphragm cells were restored with the dystrophin isoform. Reversal of differential 
proteins involved in DGC, calcium handling, and energy production were significantly 
expressed. Although this therapy appears promising skipping over a single exon in 
such a large gene will only serve to treat a small number of suitable candidates and 
provide them with a milder form of the disease and tailored therapy would prove costly 
at this early stage of the development.   
 
So many neuromuscular disorders are involved with this membrane-spanning 
complex that a detailed investigation into its assembly, maintenance and interactions in 
healthy fibres versus its dysfunction in muscular dystrophic tissue is warranted. A 
proteomic study inclusive of the high-molecular mass proteins unable to enter a 
traditional 2D polyacrylamide gel with subsequent mass spectrometric identification 
may give insight into the fate of proteins over the progression of muscular dystrophies. 
The detailed comparison into severely affected diaphragm, mildly dystrophic 
gastrocnemius, and spared extraocular, toe or laryngeal fibres may provide new 
insights into the protective mechanisms that counteract dystrophic abnormalities. An 
aging study of MDX tissues may produce interesting results to demonstrate whether 
irreversible alterations might occur in tissues that lack Dp427, which would be 
important for therapeutic value.  
 
Through proteomic profiling, we observed changes in essential proteins that might be 
useful for the future improvement of differential diagnostic procedures. This makes 
these proteins potential pharmacological targets for the development of future 
therapies to treat DMD. 
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